

# Publications and Presentations

J.L. (Hans) Severens

Version: 22/07/2021 09:25:00

## Peer reviewed publications

1. Boonen A, Putrik P, Marques ML, Alunno A, Abasolo L, Beaton D, Betteridge N, Bjørk M, Boers M, Boteva B, Fautrel B, Guillemin F, Mateus EF, Nikiphorou E, Pentek M, Pimentel Santos F, Severens J, Verstappen SMM, Walker-Bone K, Karlsson Wallman, J, Ter Wee MM, Westhovens R, Ramiro S. EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. *Ann Rheum Dis* (accepted for publication).
2. Mandrik O, Tolma E, Zielonke N, Meheus F, Ordóñez-Reyes C, Severens JL, Murillo R. Systematic reviews as a "lens of evidence": determinants of participation in breast cancer screening. *J Med Screen* (accepted for publication).
3. Lenk E, Bossinesq M, Kamgo J, Nana-Djeunga HC, Peultier ACMM, Klion AD, Nutman TB, Fletcher DA, Pion SD, Niamsi-Emalio Y, Redekop WK, Severens JL, Stolk WA. A test-and-not-treat strategy for onchocerciasis elimination in Loa loa co-endemic areas: cost analysis of a pilot in the Soa health district, Cameroon. *Clin Infect Dis* (accepted for publication).
4. Mandrik O, Ekwunife MI, Meheus F, Severens JL, Lhachimi S, Uyl-de Groot CA, Murillo R. Systematic reviews as a "lens of evidence": determinants of cost-effectiveness of breast cancer screening. *Cancer Med* DOI: 10.1002/cam4.2498 (accepted for publication)
5. Mandrik O, Severens JL, Bardach A, Ghabri S, Hamel C, Mathes T, Vale L, Wislow T, Goldhaber J. Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report. *Value Health* 2021; 24 (4): 463-472.
6. Peultier AC, Venetsanos D, Rashid I, Severens JL, Redekop WK. European survey on acute coronary syndrome diagnosis and revascularisation treatment: Assessing differences in reported clinical practice with a focus on strategies for specific patient cases. *J Eval Clin Pract* 2020; 26: 1457-1466.
7. Albuquerque de Almeida F, Al MJ, Koymans R, Riistama J, Pauws S, Severens JL. Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. *Health Qual Life Outcomes*. 2020; 18 (1): 262.
8. Peultier ACMM, Pandya A, Sharma R, Severens JL, Redekop WK. Cost-effectiveness of mechanical thrombectomy more than 6 hours after symptom onset among patients with acute aschemic stroke. *JAMA Network Open* 2020; 3 (8): 1-14.
9. Schwab B, Wimmer W, Severens JL, Caversaccio MD. Adverse events associated with bone conduction and middle ear implants: a systematic review. *Eur Arch Otorhinolaryngol* 2020; 277 (2): 423-438.
10. Buyukaramikli NC, Rutten-van Molken MPMH, Severens JL, Al M. TECH-VER: A verification checklist to reduce errors in models and improve their credibility *Pharmacoeconomics* 2019; 37 (11): 1391-1408.
11. Peultier AC, Redekop WK, Allen M, Peters J, Eker OF, Severens JL Exploring the cost-effectiveness of mechanical thrombectomy beyond six hours following advanced imaging in the UK. *Stroke* 2019; 50 (11): 3220-3227.
12. Peultier AC, Redekop WK, Dippel DWJ, Bereczki D, Si-Mohamed S, Douek PC. Severens, JL. What stroke image do we want? European survey on acute stroke imaging and revascularisation treatment. *Health Policy and Technology* 2019; 8 (3): 261-267.
13. Lin Li, Severens JL, Mandrik O. Disutility associated with cancer screening programs: A systematic review. *PloS ONE* 2019; 14 (7).
14. Grustam AS, Buyukkaramikli N, Koymans R, Vrijhoef HJM, Severens JL. Value of information analysis in telehealth for chronic heart failure management. *PloS ONE* 2019; 14 (6).

15. Mandrik O, Zielonke N, Meheus F, Severens JLH, Guha N, Herrero Acosta R, Murillo R. Systematic reviews as a 'lens of evidence': determinants of benefits and harms of breast cancer screening. *Int J Cancer*. 2019; 145 (4): 994-1006.
16. Knies S, Severens JL, Brouwer WBF. Integrating clinical and economic evidence in clinical guidelines: More needed than ever! *J Eval Clin Pract* 2019; 25 (4): 561-4.
17. Grustam AS, Severens JL, De Massari D, Buyukkaramikli N, Koymans R, Vrijhoef HJM. Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management. *Value Health*. 2018; 21 (7): 772-782.
18. Lenk EJ, Redekop WK, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, Tediosi F, Rijnsburger AJ, Bakker R, Hontelez JAC, Richardus JH, Jacobson J, Le Rutte EA, de Vlas SJ, Severens JL. Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. *PLoS Negl Trop Dis*. 2018; 12 (3).
19. Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic Analysis of Vaccination Programs. *Value Health*. 2018; 21 (10): 1133-1149.
20. Vaidya A, Kleinegris MC, Severens JL, Ramaekers BL, Ten Cate-Hoek AJ, Ten Cate H, Joore MA. Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. *J Comp Eff Res* 2018; 7 (6): 535-548.
21. Van Baal P, Morton A, Severens JL. Health care input constraints and cost effectiveness analysis decision rules. *Soc Sci Med*. 2018; 200: 59-64.
22. Peultier AC, Redekop K, Coche E, Severens JL. What are the images used to diagnose and assess suspected strokes? A systematic literature review of care in four European countries. *Expert Rev Pharmacoecon Outcomes Res*. 2018; 18 (2): 177-189.
23. Albuquerque De Almeida F, Al M, Koymans R, Caliskan K, Kerstens A, Severens JL. Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. *Expert Rev Pharmacoecon Outcomes Res*. 2018; 18 (2): 161-175.
24. Grustam AS, Vrijhoef H, Cordella A, Koymans R, Severens JL. Care coordination in a business-to-business and a business-to-consumer model for telemonitoring patients with chronic diseases. *Int J Care Coord*. 2017; 20 (4): 135-147.
25. Grustam A, Vrijhoef HJM, Koymans R, Hukal P, Severens JL. Assessment of a business-to-consumer (B2C) model for telemonitoring patients with chronic heart failure. *BMC Med Inform Decis Mak* 2017; 17 (1): 145.
26. Ceonodolea AD, Bal R, Severens JL. Epidemiology and management of atrial fibrillation and stroke; review of data from four European countries. *Stroke Res Treatment Stroke Res Treat*. 2017; 8593207. doi: 10.1155/2017/8593207.
27. Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ. Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE Single Technology Appraisal. *Pharmacoeconomics*. 2017; 35 (12): 1211-1221.
28. Houben E, van Haalen HG, Sparreboom W, Overbeek JA, Ezendam NP, Pijnenborg JM, Severens JL, Van Herk-Sukel MP. Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes. *Medical Oncology Med Oncol*. 2017; 34 (4): 50.
29. Ramaekers BL, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA. Abiraterone acetate for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer: an Evidence Review Group perspective of an NICE single technology appraisal. *Pharmacoeconomics* 2017; 35 (6): 665-667.  
Response to Letter to the Editor. *Pharmacoeconomics* 2017 Jun;35(6):665-667.
30. Redekop WK, Lenk EJ, Luyendijk M, Fitzpatrick C, Niessen L, Stolk WA, Tediosi F, Rijnsburger AJ, Bakker R, Hontelez JA, Richardus JH, Jacobson J, de Vlas SJ, Severens JL. The socioeconomic benefit to individuals of

achieving the 2020 targets for five preventive chemotherapy neglected tropical diseases. *PLoS Negl Trop Dis*. 2017; 11 (1).

31. Hifinger M, Hiligsmann M, Ramiro S, Severens JL, Fautrel B, Watson V, Boonen A. Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. *Rheumatology*. 2017; 56 (1): 68-76.
32. Burgers LT, Redekop WK, Al MJ, Lhachimi SK, Armstrong N, Walker S, Rothery C, Westwood M, Severens JL. Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients. *Eur J Health Econ*. 2017; 18 (6): 731-742.
33. Ramaekers BLT, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, Armstrong N, Severens JL, Kleijnen J, Joore MA. Abiraterone acetate for the treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer: an evidence review group perspective of an NICE Single Technology Appraisal. *Pharmacoeconomics*. 2017; 35 (2): 191-202.
34. Mandrik O, Ekwunife OI, Zielonke N, Meheus F, Severens JL, Lhachimi SK, Murillo R. What determines the effects and costs of breast cancer screening? A protocol of a systematic review of review. *Syst Reviews* 2017; 6 (1): 122.
35. Hifinger M, Hiligsmann M, Ramiro S, Watson V, Severens JL, Fautrel B, Uhlig T, van Vollenhoven R, Jacques P, Detert J, Canas da Silva J, Scirè CA, Berghea F, Carmona L, Péntek M, Keat A, Boonen A. Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. *Ann Rheum Dis* 2017; 76 (1): 126-132.
36. Hifinger M, Hiligsmann M, Ramiro S, Watson V, Berghea F, Péntek M, Keat A, Severens JL, Fautrel B, Boonen A. Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists. *RMD Open* 2017; 3 (2).
37. Burgers LT, van de Wetering FT, Severens JL, Redekop WK. Using meta-regression analyses in addition to conventional systematic review methods to examine the variation in cost-effectiveness results - a case study. *BMC Health Serv Res* 2016; 16: 23.
38. Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, Claassen J, Leentjens AF, Wolfs CA, Severens JL, Verhey FR. Added prognostic value of cerebrospinal fluid biomarkers in predicting decline in memory clinic patients in a prospective cohort. *J Alzheimers Dis*. 2016; 52 (3): 875-85.
39. Westwood M, Ramaekers B, Lang S, Armstrong N, Noake C, de Kock S, Joore M, Severens J, Kleijnen J. ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis. *Health Technol Assess* 2016; 20 (67): 1-177.
40. Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ. Lenalidomide for the treatment of low- or intermediate-1-risk myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality: an evidence review of the NICE submission from Celgene. *Pharmacoeconomics* 2016; 34 (1): 23-31.
41. Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, Duffy S, Worthy G, Al M, Severens J, Kleijnen J. Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. *Health Technol Assess* 2016; 20 (17):1-250.
42. Burgers LT, Vahl AC, Severens JL, Wiersema AM, Cuypers PW, Verhagen HJ, Redekop WK. The cost-effectiveness of elective endovascular aneurysm repair versus open surgical repair of abdominal aortic aneurysms. *Eur J Vasc Endovasc Surg* 2016; 52 (1): 29-40.
43. Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH. Upfront genotyping of DPYD\*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. *J Clin Oncol* 2016; 34 (3): 227-34).  
Deenen MJ, Cats A, Severens JL, Beijnen JH, Schellens JH. Reply to T. Magnes et al. *J Clin Oncol*. 2016 Jul 10; 34 (20): 2434-5.

44. Burgers LT, McClennan EA, Hoefler IE, Pasterkamp G, Jukema JW, Horsman S, Pijls NHJ, Walterberger J, Hillaert MA, Stubbs AS, Severens JL, Redekop WK. Treatment variation in stent choice in patients with stable or unstable coronary artery disease. *Neth Heart J* 2016; 24 (2): 110-9.
45. Lenk EJ, Redekop WK, Luyendijk M, Rijnsburger AJ, Severens JL. Productivity loss related to Neglected Tropical Diseases Eligible for Preventive Chemotherapy: A Systematic Literature Review. *PLoS Negl Trop Dis* 2016; 10 (2).
46. Ignatyeva VI, Severens JL, Corro Ramos I, Galstyan GR, Avxentyeva MV. Costs of hospital stay in specialized diabetic foot department in Russia. *Value Health Reg Issues* 2015; 7: 80-86.
47. Mandrik O, Knies S, Kalo Z, Severens JL. Reviewing transferability in economic evaluations originating from Eastern Europe. *Int J Techn Assess Health Care* 2015; 31 (6): 434-41.
48. Frederix GW, Severens JL, Hövels AM, van Hasselt JG, Hooiveld MJ, Neven P, Raaijmakers JA, Schellens JH. Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium. *Eur J Cancer Care* 2015; 24 (3): 340-354.
49. Alayli-Goebbels AF, Van Exel J, Ament AJ, De Vries NK, Bot SD, Severens JL. Consumer willingness to invest money and time for benefits of lifestyle behavior change: An application of the contingent valuation method. *Health Expect* 2015; 18 (6):2252–2265.
50. Van Gestel A, Webers CA, Beckers HJ, Peeters A, Severens JL, Schouten JS. Ocular hypertension and the risk of blindness. *J Glaucoma* 2015; 24 (1): 9-11.
51. Bouwmans C, Krol M, Severens JL, Koopmanschap M, Brouwer W, Hakkaart-van Roijen L. The iMTA Productivity Cost Questionnaire A standardized instrument for measuring and valuing health related productivity losses. *Value Health* 2015; 18 (6): 753-758.
52. Tran-Duy A, Boonen A, Van der Laar MAFJ, Severens JL. Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-alpha antagonists in management of ankylosing spondylitis: a dynamic population modelling study. *BMC Cost Effectiveness and Resource Allocation* 2015; 13: 18.
53. Handels RLH, Joore MA, Tran-Duy A, Wimo A, Wolfs CAG, Verhey FRJ, Severens JL. Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment. *Alzheimer's & Dementia* 2015; 11: 896-905.
54. Frederix GWJ, Severens JL, Hövels AM. Use of quality checklists and need for disease specific guidance in economic evaluations; a meta-review. *Expert Rev Pharmacoecon Outcomes Res* 2015; 15 (4): 675-685.
55. Mandrik O, Knies S, Severens JL. Economic value of in-vitro fertilization in Ukraine, Belarus, and Kazakhstan. *Clin Econ Outcomes Res CEOR* 2015; 7: 347-356.
56. Mandrik O, Corro Ramos I, Knies S, Al M, Severens JL. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. *Cancer Manag Res* 2015; 7: 279–289.
57. Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N, Ryder S, Stirk L, Severens J, Kleijnen J. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015; 19 (96):1-236.
58. Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens JL, Kleijnen J. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015; 19 (58): 1- 228.
59. Westwood M, Van Asselt T, Ramaekers B, Whiting P, Thokala P, Joore M, Armstrong N, Ross J, Severens J, Kleijnen J. High-sensitivity troponin assays for the early rule-out or diagnosis of acute myocardial infarction in people with acute chest pain: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2015; 19 (44): 1-234.

60. Frederix GWJ, Hövels AM, Severens JL, Raaijmakers JAM, Schellens JHM. Drempelwaarde bij vergoeding van nieuwe medicatie; Doelmatigheidsonderzoek en modellering als onmisbare schakels. *Ned Tijdschr Geneeskd.* 2015;159: A7728
61. Van Haaren-ten Haken TM, Hendrix M, Smits LJ, Nieuwenhuijze MJ, Severens JL, De Vries RG, Nijhuis JG. The influence of preferred place of birth on the course of pregnancy and labor among healthy pregnant women: a prospective cohort study. *BMC Pregnancy Childbirth* 2015; 15 (1): 455.
62. Hiligsmann M, Cooper C, Guillemin F, Hochberg MC, Tugwell P, Arden N, Berenbaum F, Boers M, Boonen A, Branco JC, Maria-Luisa B, Bruyère O, Gasparik A, Kanis JA, Kvien TK, Martel-Pelletier J, Pelletier JP, Pinedo-Villanueva R, Pinto D, Reiter-Niesert S, Rizzoli R, Rovati LC, Severens JL, Silverman S, Reginster JY. A reference case for economic evaluations in osteoarthritis. An Expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum* 2014; 44: 271-282 .
63. Knies S, Boonen A, Severens JL. Do the Washington Panel recommendations hold for Europe? Investigating the relation between quality of life versus work-status, absenteeism and presenteeism. *BMC Cost Effectiveness Resource Allocation* 2014, 12: 24.
64. Handels RLH, Wolfs CAG, Aalten P, Bossuyt PMM, Joore MA, Leentjens AFG, Severens JL, Verhey FRJ. Optimizing the use of expert panel reference diagnoses in diagnostic studies of multidimensional syndromes. *BMC Neurology* 2014, 14: 190.
65. Vaidya A, Joore MA, Ten Cate-Hoek AJ, Ten Cate H, Severens JL. Cost-effectiveness of risk assessment and tailored treatment for Peripheral Arterial Disease patients. *Biomark Med* 2014; 8 (8): 989-999.
66. Van Gestel A, Schouten JS, Beckers HJ, Severens JL, Hendrikse F, Webers CA. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension. *Acta Ophthalmol* 2014; 92 (6): 513-523.
67. Ramos GFP, Van Asselt ADI, Kuiper S, Severens JL, Maas T, Dompeling E, Knottnerus JA, Van Schayck CP. Cost-effectiveness of primary prevention of paediatric asthma—a decision-analytic model. *Eur J Health Econ*: 2014; 15 (8); 869-883.
68. Burgers LT, Nauta ST, Deckers JW, Severens JL, Redekop WK. Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment? *Int J Cardiol* 2014; 176 (3): 980-987.
69. Armstrong N, Burgers L, Deshpande S, Al M, Riemsma R, Vallabhaneni S, Holt P, Severens J, Kleijnen J. The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. *Health Technol Assess.* 2014; 18 (70): 1-66.
70. Westwood M, Van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2014; 18 (62): 1-132.
71. Benning TM, Dellaert BG, Dirksen CD, Severens JL. Preferences for potential innovations in non-invasive colorectal cancer screening: A labeled discrete choice experiment for a Dutch screening campaign. *Acta Oncol* 2014; 53 (7): 898-908.
72. Handels RL, Wolfs CA, Aalten P, Joore MA, Verhey FR, Severens JL. Diagnosing Alzheimer's disease: a systematic review of economic evaluations. *Alzheimers Dement* 2014; 10 (2): 225-237.
73. Alayli-Goebbels AFG, Evers SMAA, Alexeeva D, Ament AJHA, De Vries NK, Tilly JC, Severens JL. A review of economic evaluations of behavior change interventions: Setting an agenda for research methods and practice. *J Public Health (Oxf)* 2014; 36 (2): 336-344.
74. Vaidya A, Severens JL, Bongaerts BWC, Cleutjens KBJM, Nelemans PJ, Hofstra L, Van Dieijen-Visser M, Biessen EAL. High-sensitive Troponin T assay for the diagnosis of acute myocardial infarction: an economic evaluation. *BMC Cardiovasc Disord* 2014; 14: 77.
75. Tran-Duy A, Boonen A, Kievit W, Van Riel PLCM, Van de Laar MA, Severens JL. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decision in patients with rheumatoid arthritis. *Pharmacoeconomics* 2014; 32 (10): 1015-1028.

76. Benning TM, Dellaert BCG, [Severens JL](#), Dirksen CD. The effect of presenting information about invasive follow-up testing on individuals' non-invasive colorectal cancer screening participation decision: Results from a discrete choice experiment. *Value Health* 2014; 17: 578-587.
77. Burgers LT, Redekop WK, [Severens JL](#). Challenges in modelling the cost effectiveness of various interventions for cardiovascular disease. *Pharmacoeconomics* 2014; 32 (7): 627-637.
78. Van Haalen HGM, [Severens JL](#), Tran-Duy A, Boonen A. How to select the right cost-effectiveness model? A systematic review and stepwise approach for selecting a transferable health economic model for rheumatoid arthritis. *Pharmacoeconomics* 2014; 32 (5): 429-442.
79. Westwood M, Joore M, Whiting P, Van Asselt T, Ramaekers B, Armstrong N, Misso K, [Severens J](#), Kleijnen J. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2014; 18 (32): 1-166.
80. Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, [Severens H](#), Kleijnen J. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2014;18 (18): 1-106.
81. Grustam AS, [Severens JL](#), Van Nijnatten J, Koymans R, Vrijhoef HJM. Cost-effectiveness of telehealth interventions for chronic heart failure patients – a literature review. *Int J Techn Assess Health Care* 2014; 30 (1): 1-10.
82. Vaidya A, Joore MA, Ten Cate-Hoek AJ, Kleinegris MC, Ten Cate H, [Severens JL](#). A systematic review of model-based economic evaluations of diagnostic and therapeutic strategies for lower extremity artery disease. *Thromb Haemos* 2014; 111 (1): 19-28.
83. Frederix GW, van Hasselt JG, Schellens JH, Hövels AM, Raaijmakers JA, Huitema AD, [Severens JL](#). The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. *Pharmacoeconomics* 2014; 32 (1): 47-61.
84. Vaidya A, Joore MA, Ten Cate-Hoek AJ, Ten Cate H, [Severens JL](#). Screen or not to screen for peripheral arterial disease: guidance from a decision model. *BMC Public Health* 2014, 14: 89.
85. Hilgsmann M, Cooper C, Arden N, Boers M, Branco JC, Brandi ML, Bruyère O, Guillemin F, Hochberg MC, Hunter DJ, Kanis JA, Kvien TK, Laslop A, Petit-Dop F, Pelletier JP, Pinto D, Reiter-Niesert S, Rizzoli R, Rovati L, [Severens JL](#), Silverman S, Tsouderos Y, Tugwell P, Reginster JY. Health economics in the field of osteoarthritis; an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Semin Arthritis Rheum* 2013; 43 (3): 303-313.
86. Riemsma R, Al M, Corro Ramos I, Deshpande SN, Armstrong N, Lee YC, Ryder S, Noake C, Krol M, Oppe M, Kleijnen J, Severens H. SeHCAT (Tauroselcholic [75Selenium] acid for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss: A systematic review and cost-effectiveness. *Health Technol Assess* 2013; 17 (61): 1- 236.
87. Mandrik O, Corro Ramos I, Zalis'ka O, Gaisenko A, [Severens JL](#). Cost for treatment of chronic lymphocytic leukemia in specialized institutions of Ukraine. *Value Health Reg Issues* 2013; 2: 205-209.
88. Deshpande S, Van Asselt T, Tomini F, Armstrong N, Allen A, Noake C, Khan K, Severens J, Kleijnen J, Westwood M. Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. *Health Technology Assessment* 2013; 17 (40): 1-138.
89. Frederix GWJ, [Severens JL](#), Hövels AM, Raaijmakers JAM, Schellens JHM. The cloudy crystal ball of cost-effectiveness studies (commentary). *Value Health* 2013; 16 (5): 1100-1102.
90. Handels, RLH, Xu W, Rizzuto D, Caracciolo B, Wang R, Winblad B, Verhey FRJ, [Severens JL](#), Fratiglioni L, Joore MA, Wimo A. Natural progression model of cognition and physical functioning among people with Mild Cognitive Impairment and Alzheimer's Disease. *J Alzheimers Dis* 2013; 137 (2): 357-365.
91. Frederix GW, [Severens JL](#), Hövels AM, Van Hasselt JG, Raaijmakers JA, Schellens JHM. Time-dependent resource use and costs associated with different states of disease in patients diagnosed with HER-2-positive metastatic breast cancer. *Breast Cancer Res Treat*. 2013; 139 (2): 489-495.

92. Frederix GW, Van Hasselt JGC, Severens JL, Hövels AM, Huitema ADR, Raaijmakers JAM, Schellens JHM. Development of a framework for cost-effectiveness analysis cohort simulation using a multi-step ordinary differential equation solver algorithm in R. *Med Decis Making* 2013; 33 (6):780-792.
93. Garrison LP, Towse A, Briggs A, De Pourvoirville G, Grueger J, Mohr P, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements; good practices for design, implementation, and evaluation: an ISPOR Task Force report. *Value Health*. 2013; 16 (5): 703-719.
94. Knies S, Boonen A, Candel MJJM, Evers SMAA, Severens JL. Compensation mechanisms for lost productivity: A comparison between four European countries. *Value Health* 2013; 16 (5): 740-744.
95. Mandrik O, Severens JL, Doroshenko O, Pan'kiv V, Kravchun N, Vlasenko M, Hulchiy M, Baljuk M, Komisarenko Y, Martsynik E, Sokolova L, Zalis'ka O, Mankovsky B. Impact of hypoglycemia on daily life of diabetic patients in Ukraine. *J Multidiscip Health* 2013; 6: 249–257.
96. Albers-Heitner P, Winkens R, Berghmans B, Joore M, Nieman F, Severens J, Lagro-Janssen, T. Consumer satisfaction among patients and their general practitioners about involving nurse specialists in primary care for patients with urinary incontinence. *Scand J Caring Sci* 2013; 27: 253-259.
97. Westwood ME, Joore MA, Grutters JPC, Redekop WK, Armstrong N, Lee K, Gloy V, Raatz H, Misso K, Severens J, Kleijnen J. Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. *Health Technol Assess* 2013; 17 (16): 1-243.
98. Handels RL, Wolfs CA, Aalten P, Verhey FR, Severens JL. Determinants of care costs of patients with dementia or cognitive impairment. *Alzheimer Dis Assoc Disord* 2013; 27 (1): 30-36.
99. Westwood M, Al M, Burgers L, Redekop K, Lhachimi S, Armstrong N, Ratz H, Misso K, Severens J, Kleijnen J. A systematic review and economic evaluation of new generation computed tomography (NGCCT) scanners for imaging in coronary artery disease and congenital heart disease - Somatom Definition Flash, Aquilion One, Brilliance iCT and Discovery CT750 HD. *Health Technol Assess* 2013; 17 (9): 1-243.
100. Alayli-Goebbels AF, Dellaert BG, Knox SA, Ament AJ, Lakerveld J, Bot SD, Nijpels G, Severens JL. Consumer preferences for health and non-health outcomes of health promotion: Results from a discrete choice experiment. *Value Health* 2013; 16 (1): 114-123.
101. Grutters JPC, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruyscher A, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. *PharmacoEconomics* 2013; 31: 111–123.
102. Mandrik O, Zalis'ka O, Severens J. Cost of treating lymphoproliferative disorders in Ukraine: pilot assessment of data (in Russian with English abstract). *Medicinskie tehnologii; Ocenka i vybor (Medical technologies; assessment and choice)* 2012; Special Issue: 73-76.
103. Krol M, Brouwer W, Severens JL, Kaper J, Evers SMAA. Productivity cost calculations in economic evaluations: correcting for compensation mechanisms and multiplier effects? *Soc Sci Med* 2012; 75: 1981-1988.
104. Handels RLH, Aalten P, Wolfs CAG, Olde Rikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FRJ. Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. *BMC Neurology* 2012; 12 (1): 72.
105. Knies S, Candel MJJM, Boonen A, Evers SMAA, Ament AJHA, Severens JL. Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable? *Pharmacoeconomics* 2012; 30 (9): 795-807.
106. Wolfs CA, Kessels A, Severens JL, Brouwer W, de Vugt ME, Verhey FR, Dirksen CD. Predictive Factors for the Objective Burden of Informal Care in People With Dementia: A Systematic Review. *Alzheimer Dis Assoc Disord* 2012; 26 (3): 197-204.
107. Alayli-Goebbels AFG, Lakerveld J, Ament AJHA, Bot SDM, Severens JL. Exploring non-health outcomes of health promotion: The perspective of participants in a lifestyle behavior change intervention. *Health Policy* 2012; 106: 177-186.

108. Albers-Heitner PC, Joore MM, Winkens RR, Lagro-Janssen TA, Severens JL, Berghmans BL. Cost-effectiveness of involving nurse specialists for adult patients with urinary incontinence in primary care compared to care-as-usual: An economic evaluation alongside a pragmatic randomized controlled trial. *Neurourol Urodyn*. 2012; 31 (4): 526-534.
109. Hoomans T, Severens JL, Van der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in the Netherlands. *Pharmacoeconomics* 2012; 30 (30): 219-227.
110. Van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. *Acta Ophthalmol*. 2012; 90 (1): 20-31.
111. Van Gestel A, Grutters J, Schouten J, Webers C, Beckers H, Joore M, Severens J. The role of the expected value of individualized care in cost-effectiveness analysis and decision making. *Value Health* 2012; 15 (1): 13-21.
112. Zhang W, Bansback N, Boonen A, Severens JL, Anis AH. Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis. *Value Health*. 2012; 15 (1): 46-54.
113. Frederix GWJ, Severens JL, Hövels AM, Raaijmakers JAM, Schellens JHM. Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. *Value Health* 2012; 15 (1): 94-105.
114. Peeters A, Schouten JASG, Severens JL, Hendrikse F, Prins MH, Webers CAB. Latanoprost versus timolol as first choice therapy in patients with ocular hypertension. A cost-effectiveness analysis. *Acta Ophthalmol* 2012; 90: 146-154.
115. Tran-Duy A, Boonen A, van de Laar MA, Franke AC, Severens JL. A discrete event modelling framework for simulation of long-term outcomes of sequential treatment strategies for ankylosing spondylitis. *Ann Rheum Dis* 2011; 70 (12): 2111-2118.
116. Ramos GF, Kuiper S, Dompeling E, van Asselt AD, de Grauw WJ, Knottnerus JA, van Schayck OC, Schermer TR, Severens JL. Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children. *BMC Med Res Methodol* 2011; 11 (1): 150.
117. Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands. *Neuropsychiatr Dis Treat* 2011; 7: 313-317.
118. Boonen A, Severens JL. Evaluating treatment strategies in patients with early rheumatoid arthritis: merging modeling theory with clinical practice. *J Rheumatol* 2011; 38 (8): 1538-1540.
119. Albers-Heitner PC, Lagro-Janssen TA, Joore MM, Berghmans BL, Nieman F, Venema P, Severens JL, Winkens R. Effectiveness of involving a nurse specialist for patients with urinary incontinence in primary care: results of a pragmatic multicentre randomised controlled trial. *Int J Clin Pract* 2011; 65 (6): 705-712.
120. Fiddelers AA, Nieman FH, Dumoulin JC, van Montfoort AP, Land JA, Evers JL, Severens JL, Dirksen CD. During IVF treatment patient preference shifts from singletons towards twins but only a few patients show an actual reversal of preference. *Hum Reprod* 2011; 26 (8): 2092-2100.
121. Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Implementing guidelines into clinical practice: what is the value? *J Eval Clin Pract*. 2011; 17 (4): 606-614.
122. Wolfs CAG, Dirksen CD, Severens JL, Kessels A, Verkaaik M, Verhey FRJ. De kosten en opbrengsten van een geïntegreerde aanpak bij dementie. *Tijdsch Psychiatr* 2011; 53 (9): 657-665.
123. De Graaf LE, Gerhards SAH, Arntz A, Riper H, Metsemakers JFM, Evers SMAA, Severens JL, Widdershoven G, Huibers MJH. One-year follow-up results of unsupported online computerised cognitive behavioural therapy for depression in primary care: a randomized trial. *J Behav Ther Exp Psychiatry*. 2011; 42 (1): 89-95.
124. Kroese ME, Severens JL, Schulpden GJ, Bessems MC, Nijhuis FJ, Landewé RB. Specialized rheumatology nurse substitutes for rheumatologists in the diagnostic process of fibromyalgia: a cost-consequence analysis and a randomized controlled trial. *J Rheumatol* 2011; 38 (7): 1413-1422.
125. Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. *Clin Rheumatol* 2011; 30 (Suppl 1): S3-S8.

126. Van Vollenhoven RF, Severens JL. Observational studies: a valuable source for data on the true value of RA therapies. *Clin Rheumatol* 2011; 30 (Suppl 1): S19-S24.
127. Van Breugel NH, Bidar E, Essers BA, Nieman FH, Accord RE, Severens JL, Vrakking R, Maessen JG. Cost-effectiveness of ablation surgery in patients with atrial fibrillation undergoing cardiac surgery. *Interact Cardiovasc Thorac Surg* 2011; 12 (3): 394-398.
128. Hendrix M, Pavlova M, Nieuwenhuijze MJ, Severens JL, Nijhuis JG. Differences in preferences for obstetric care between nulliparae and their partners in the Netherlands: a discrete-choice experiment. *J Psychosom Obstet Gynaecol* 2010; 31 (4): 243-251.
129. Houweling H, Wittevrongel CFW, Verweij M, Ruitenber EJ on behalf of the National Immunisation Programme Review Committee of the Health Council of the Netherlands. Public vaccination programmes against hepatitis B in the Netherlands: assessing whether a targeted or a universal approach is appropriate. *Vaccine* 2010; 28 (49):7723-7730.
130. Van Gestel A, Webers CA, Beckers HJ, van Dongen MC, Severens JL, Hendrikse F, Schouten JS. The relationship between visual field loss in glaucoma and health-related quality-of-life. *Eye* 2010; 24 (12): 1759-1769.
131. Van Heesch MM, Bonsel GJ, Dumoulin JC, Evers JL, Van der Hoeven MA, Severens JL, Dykgraaf RH, Van der Veen F, Tonch N, Nelen WL, Van Zonneveld P, Van Goudoever JB, Taminga P, Steiner K, Koopman-Esseboom C, Van Beijsterveldt CE, Boomsma DI, Snellen D, Dirksen CD. Long term costs and effects of reducing the number of twin pregnancies in IVF by single embryo transfer: the TwinSing study. *BMC Pediatr* 2010; 10: 75.
132. Barbieri M, Drummond M, Rutten F, Cook J, Glick HA, Lis J, Reed SD, Sculpher M, Severens JL. ISPOR Good Research Practices Economic Data Transferability Task Force. What do international pharmacoeconomic guidelines say about economic data transferability? *Value Health* 2010; 13 (8): 1028-1037.
133. Grutters JPC, Pijls-Johannesma M, De Ruyscher D, Peeters A, Reimoser S, Severens JL, Lambin Ph, Joore MA. The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research. *Cancer Treat Rev* 2010; 36 (6): 468-476.
134. Vercauteren LD, Kessels AG, Van der Weijden T, Severens JL, Van Engelshoven JM, Flobbe K. Association between guideline adherence and clinical outcome for patients referred for diagnostic breast imaging. *Qual Saf Health Care* 2010; 19 (6): 503-508.
135. Van Keulen H, Bosmans JE, Van Tulder M, Severens JL, De Vries H, Brug J, Mesters I. Cost-effectiveness of tailored print communication, telephone motivational interviewing, and a combination of the two: results of an economic evaluation alongside the Vitalum randomized controlled trial. *Int J Behav Nutr Phys Activit* 2010; 7: 64.
136. Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of valuing lost productivity across jurisdictions; differences between national pharmacoeconomic guidelines. *Value Health* 2010; 13(5): 519-527.
137. Van Mastrigt GAPG, Joore MA, Nieman FHM, Severens JL, Maessen JG. Health-related quality of life after fast-track treatment; results from a randomized controlled clinical equivalence trial. *BMC Qual Life Res* 2010; 19: 631-642.
138. Boonen A, Brinkhuizen T, Landewé, Van der Heijden D, Severens JL. Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. *Ann Rheum Dis* 2010; 69: 1123-1128.
139. Hoomans T, Van der Roer N, Severens JL, Delwel G. Kosten-effectiviteit van nieuwe geneesmiddelen van belang bijgeneesmiddelvergoeding, maar voor verbetering vatbaar. *NTvG* 2010; 154 (30): 1406-1414.
140. Essers BAB, Seferina SC, Tjan-Heijnen VCG, Severens JL, Novak A, Pompen M, Oron UH, Joore MA. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. *Value Health* 2010; 13 (4): 375-380.
141. Van Gestel A, Severens JL, Webers CAB, Beckers HJM, Jansonius NM, Schouten JSAG. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. *Value Health* 2010; 13 (4): 358-367.

142. Joore MA, Brunenberg DEM, Nelemans PJ, Wouters E, Kuijpers PMJC, Honig A, Willems D, De Leeuw PW, Severens JL, Boonen A. Comparing cost-utility ratios based on EQ-5D and SF-6D studies. *Value Health* 2010; 13 (2): 222-229.
143. Van Breugel HNAM, Niemann FHM, Accord RE, Van Mastrigt GAPG, Nijs JFMA, Severens JL, Vrakking R, Meassen JG. A prospective randomised multicentre comparison on health related quality of life: the value of add-on arrhythmia surgery in patients with paroxysmal, permanent or persistent atrial fibrillation undergoing valvular and/or coronary bypass surgery. *J Cardio Electrophys* 2010; 21: 511-521.
144. Scholtissen S, Bruyère O, Neuprez A, Severens JL, Herrero-Beaumont G, Rovati L, Hilgsmann M, Reginster JY. Glucosamine sulfate in the treatment of knee osteoarthritis: cost-effectiveness comparison with acetaminophen. *Int J Clin Pract* 2010; 64 (6): 756-762.
145. De Graaf E, Gerhards S, Arntz A, Riper H, Metsemakers J, Evers S, Severens H, Widdershoven G, Huibers M. Effectiviteit van online cognitieve gedragstherapie voor depressie in de eerste lijn. *Gedragstherapie* 2010; 43: 59-77.
146. Houweling H, Verweij M, Ruitenbergh EJ on behalf of the National Immunisation Programme Review Committee of the Health Council of the Netherlands. Criteria for inclusion of vaccinations in public programmes. *Vaccine* 2010; 28 (17):2924-2931.
147. Wyers CE, Breedveld-Peters JJ, Reijven PL, van Helden S, Guldmond NA, Severens JL, Verburg AD, Meesters B, van Rhijn LW, Dagnelie PC. Efficacy and cost-effectiveness of nutritional intervention in elderly after hip fracture: design of a randomized controlled trial. *BMC Public Health*. 2010; 10: 212.
148. Peeters A, Grutters JPC, Pijs-Johannesma M, Reimoser S, De Ruyscher, Severens JL, Joore MA, Lambin Ph. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. *Radiotherap Oncol* 2010; 95: 45-53.
149. Gerhards SAH, De Graaf LE, Jacobs LE, Severens JL, Huibers MJH, Arntz A, Riper H, Widdershoven G, Metsemakers JFM, Evers SMAA. Economic evaluation of online computerized cognitive-behavioural therapy without support for depression in primary care: randomized trial. *Brit J Psych* 2010; 196: 310-318.
150. Koelewijn – van Loon MS, Van der Weijden T, Van Steenkiste B, Ronda G, Winkens B, Severens JL, Wensing M, Elwyn G, Grol R. Involving patients in cardiovascular risk management using nurse-led clinics: a cluster-randomised controlled trial in primary care. *Can Med Assoc J* 2009; 181 (12): 267-274.
151. Hendrix MJC, Evers SMAA, Basten MCM, Nijhuis JG, Severens JL. Cost Analysis of the Dutch Obstetric System: low-risk nulliparous women preferring home or short-stay hospital birth - a prospective non-randomised controlled study. *BMC Health Serv Res* 2009, 9: 211.
152. Van Eijsden-Besseling MDF, Gerhards SA, De Bie RA, Severens JL. Cost-effectiveness of postural exercise therapy versus physiotherapy in computer screen workers with early non-specific work-related upper limb disorders (WRULD); a randomized controlled trial. *Trials* 2009, 10: 103.
153. Van Schayck CP, Kaper J, Wagena EJ, Wouters EFM, Severens JL. The cost-effectiveness of antidepressants for smoking cessation in COPD patients. *Addiction* 2009; 104: 2110-2117.
154. Hoomans T, Abrams KR, Ament AJHA, Evers SMAA, Severens JL. Modelling the value for money of changing clinical practice change: a stochastic application in diabetes care. *Med Care* 2009; 47 (10): 1053-61.
155. Kroese M, Schulpen G, Bessems M, Nijhuis F, Severens J, Landewé R. The feasibility and efficacy of a multidisciplinary intervention with aftercare meetings for fibromyalgia. *Clin Rheumatol* 2009; 28: 923-929.
156. Knies S, Evers SMAA, Candell MJJM, Severens JL, Ament AJHA. Utilities of the EQ-5D: transferable or not? *Pharmacoeconomics* 2009; 27 (9): 767-779.
157. Van Asselt ADI, Van Mastrigt GAPG, Dirksen CD, Arntz A, Severens JL, Kessels AGH. How to deal with cost-differences at baseline. *Pharmacoeconomics* 2009; 27 (6): 519-528.
158. Hövels AM, Heesakkers RA, Adang EM, Barentsz JO, Jager GJ, Severens JL. Cost-effectiveness of MR lymphography for the detection of lymph node metastases in patients with prostate cancer. *Radiology*. 2009; 252 (3): 729-736.

159. Franke LC, Ament AJHA, Van der Laar MAFJ, Boonen A, Severens JL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol* 2009; 27 (suppl. 55): S117-S122.
160. Willems DCM, Joore MA, Nieman FHM, Severens JL, Wouters EFM, Hendriks JE. Using the EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. *Int J Tech Ass Health Care* 2009; 25 (3): 391-399.
161. De Graaf LE, Gerhards SAH, Arntz AR, Riper H, Metsemakers JFM, Evers SMAA, Severens JL, Widdershoven G, Huibers MJH. Clinical effectiveness of online computerized cognitive behavioural therapy without support for depression in primary care: a randomized trial. *Brit J Psych* 2009; 105: 73-80.
162. Knies S, Ament AJHA, Evers SMAA, Severens JL. The transferability of economic evaluations; testing the model of Welte. *Value Health* 2009; 12 (5): 730-738.
163. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. *Value Health* 2009; 12 (4): 409-418.
164. Fiddellers AA, Dirksen CD, Dumoulin JC, van Montfoort AP, Land JA, Janssen JM, Evers JL, Severens JL. Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model. *Human Reprod* 2009; 24 (7): 1648-1655.
165. Hoomans T, Severens JL, Evers SMAA, Ament AJHA. Value for money in changing clinical practice: should decisions about guidelines and implementation strategies be made sequentially or simultaneously? *Med Decis Making* 2009; 29: 207-216.
166. Van Asselt ADI, Dirksen CD, Arntz A, Giesen JH, Severens JL. The EQ-5D: A useful assessment instrument in borderline personality disorder? *Eur Psych* 2009; 24: 79-85.
167. Hendrix M, Van Horck M, Moreta D, Nieman F, Nieuwenhuijze M, Severens J, Nijhuis J. Why women do not accept randomisation for place of birth: feasibility of a RCT in the Netherlands. *Brit J Obstet Gynaecol* 2009; 116 (4): 537-542.
168. Wolfs CAG, Dirksen CD, Kessels A, Severens JL, Verhey FRJ. Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. *Arch Gen Psych* 2009; 66 (3): 313-323.
169. Smeets RJ, Severens JL, Beelen S, Vlaeyen JW, Knottnerus JA. More is not always better: Cost-effectiveness analysis of combined, single behavioural and single physical rehabilitation programs for chronic low back pain. *Eur J Pain* 2009; 13: 71-81.
170. Van Asselt ADI, Dirksen CD, Arntz A, Severens JL. Difficulties in calculating productivity costs; work disability associated with borderline personality disorder. *Value Health* 2008; 11 (4): 637-644.
171. Peeters A, Schouten JS, Weber CA, Prins MH, Hendrikse, Severens JL. Cost-effectiveness of early detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. *Eye* 2008; 22 (3):354-362.
172. Vercauteren LDB, Kessels AGH, Weijden T van der, Koster D, Severens JL, Engelshoven JMA van, Flobbe K. Clinical impact of the use of additional ultrasonography in diagnostic breast imaging. *Eur Radiol* 2008; 18 (10): 2076-2084.
173. Goebbels A, Ament A, Novak A, Veraart C, Severens J. Estimating the Implicit Value of Statistical Life based on public interventions implemented in The Netherlands. *Int J Tech Ass Health Care* 2008; 24 (4): 495-501.
174. Knies S, Severens JL, Ament AJHA, Evers SMAA. Using cost-effectiveness results from abroad for local policy decisions. *Eur J Hosp Pharm* 2008; 14: 51-54.
175. Kroese MEAL, Schulpen GJC, Bessems MCM, Severens JL, Nijhuis FJ, Geusens PP, Landewe RB. Substitution of specialised rheumatology nurses for rheumatologists in the diagnostic process of fibromyalgia: a randomized controlled trial. *Arthr C Res* 2008; 59 (9): 1299-1305.
176. Heesakkers RAM, Hövels AM, Jager GJ, Van den Bosch HCM, Witjes A, Raat HPJ, Severens JL, Adang EMM, Hulsbergen van der Kaa C, Fütterer JJ, Barentsz J. MRI with a lymph node specific contrast agent as an

- alternative to CT-scan and lymph node dissection in patients with prostate cancer: a prospective multicohort study. *Lancet Oncol.* 2008; (9):850-856.
177. Scheeres K, Wensing M, Bleijenberg G, Severens J. Implementing cognitive behaviour therapy for chronic fatigue syndrome in mental health care: a costs and outcomes analysis. *BMC Health Serv Res* 2008; 8: 175.
  178. Scheeres K, Wensing M, Severens H, Adang E, Bleijernberg G. Determinants of health care use in chronic fatigue syndrome patients: a cross sectional study. *J Psych Res* 2008; 65: 39-46.
  179. Keulen van HM, Mesters I, Brug J, Ausems M, Campbell M, Resnicow K, Zwietering PJ, Breukelen van G, Mechelen van W, Severens JL, Vries de H. Vitalum study design: RCT evaluating the efficacy of tailored print communication and telephone motivational interviewing on multiple health behaviours. *BMC Public Health* 2008; 8: 216.
  180. Willems DCM, Joore MA, Hendriks JJE, Niemann FHM, Severens JL, Wouters EFM. The effectiveness of nurse-led telemonitoring of asthma: results of a randomised controlled trial. *J Eval Clin Pract* 2008; 14 (4): 600-609.
  181. Den Hartog JE, Lardenoije CMJG, Severens JL, Land JA, Evers JLH, Kessels AGH. Screening strategies for tubal factor subfertility. *Human Reproduction* 2008; 23: 1840-1848.
  182. De Graaf E, Gerhards SAH, Evers SMAA, Arntz A, Riper H, Severens JL, Widdershoven G, Metsemakers JFM, Huibers MJH. Clinical and cost-effectiveness of computerised cognitive behavioural therapy for depression in primary care: design of a randomised trial. *BMC Public Health* 2008; 8: 224.
  183. Albers-Heitner PCP, Berghmans BLCM, Joore MA, Lagro-Janssen ALM, Severens JL, Nieman F, Winkens RAG. Study protocol: The effects of involving a nurse practitioner in primary care for adult patients with urinary incontinence: the PromoCon study (Promoting Continence). *BMC Health Serv Res* 2008; 8: 84.
  184. Van Asselt ADI, Dirksen CD, Arntz A, Giesen-Bloo JH, Van Dyck R, Spinhoven P, Van Tilburg W, Ismay P, Nadort M, Severens JL. Outpatient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. *Brit J Psych* 2008; 192: 450-457.
  185. Wolfs CAG, Kessels A, Dirksen C, Severens JL, Verhey F. Integrated multidisciplinary diagnostic approach for dementia care: a randomised controlled trial. *Brit J Psych* 2008; 192 (4): 300-305.
  186. Martens JD, Van der Weijden T, Winkens RAG, Kester ADM, Geerts PJ, Evers SMAA, Severens JL. Feasibility and acceptability of a computerised system with automated reminders for prescribing behaviour in primary care. *Int J Med Inform* 2008; 77 (3):199-207.
  187. Hövels AM, Heesakkers RAM, Adang EM, Jager GJ, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer. A meta-analysis. *Clin Rad* 2008; 63 (4): 387-95.
  188. Timmer-Bonte JNH, Adang EMM, Termeer E, Severens JL, Tjan-Heijnen VCG. Modeling the cost-effectiveness of secondary FN-prophylaxis during standard-dose chemotherapy. *Journal of Clinical Oncology* 2008; 26 (2): 290-296.
  189. Martens JD, Van der Weijden T, Severens JL, De Clercq PA, De Bruyn DP, Kester ADM, Winkens RAG. The effect of computer reminders on GPs' prescribing behaviour: a cluster randomized trial. *Int J Med Informatics* 2007; 76 (suppl 3): S403-S416.
  190. Van Asselt ADI, Dirksen CD, Arntz A, Severens JL. The cost of borderline personality disorder; societal cost of illness in BPD-patients. *Eur Psych* 2007; 22: 354-361.
  191. Wolfs CAG, Dirksen CD, Kessels A, Willems DCM, Verhey FRJ, Severens JL. Performance of the EQ-5D and the EQ-5D+C in elderly patients with cognitive impairments. *BMC Health Qual Life Outc* 2007; 5: 33.
  192. Willems DCM, Joore MA, Hendriks JJE, Van Duurling RAH, Wouters EFM, Severens JL. Process evaluation of a nurse-led telemonitoring programme for patients with asthma. *J Telemed Telecare* 2007; 13: 310-317.
  193. Willems DCM, Joore MA, Hendriks JJ, Wouters EFM, Severens JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. *BMC Cost Eff Resour Alloc* 2007; 5: 10.

194. Ament JHA, Hübben MWA, Verweij PE, De Groot R, Warris A, Donnelly JP, Van het Wout J, Severens JL. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. *J Antimicrobial Chemotherapy*. 2007; 60: 385-393.
195. Martens JD, Werkhoven MJ, Severens JL, Winkens RAG. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners. *J Eval Clin Pract* 2007; 13: 369-373.
196. Van Montfoort APA., Fiddelers AAA. Land JA, Dirksen CD, Severens JL, Geraedts JPM, Evers JLH, Dumoulin JCM. eSET irrespective of the availability of a good-quality embryo in the First cycle only is not effective in reducing overall twin pregnancy rates. *Hum Reprod* 2007; 22: 1669-1674.
197. Brunenberg DEM, Wetzels GEC, Nelemans PJ, Dirksen CD, Stoffers HEJH, Schouten JSAG, Prins MH, Severens JL, Leeuw, PW de, Joore MA. Costs and cost-effectiveness of an adherence improving program in hypertensive patients. *Pharmacoeconomics* 2007; 25: 239-251.
198. Hoomans T, Evers SMAA, Ament AJHA, Hubben M, Van der Weijden T, Grimshaw J, Severens JL. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. *Value Health* 2007; 10: 305-316.
199. Knoester PD, Deckers CLP, Termeer EH, Boendermaker AJ, Kotsopoulos IAW, De Krom MCTFM, Keyser A, Renier WO, Hekster YA, Severens JL. A cost-effectiveness decision model for antiepileptic drug treatment in newly diagnosed epilepsy patients. *Value Health* 2007; 10 (3): 173-182.
200. Steuten LMG, Palmer SJ, Vrijhoef HJM, Van Merode GG, Spreeuwenberg C, Severens JL. Cost-utility of a disease management program for patients with asthma. *Int J Techn Assessm Health Care* 2007; 23: 184-191.
201. Costa-Scharplatz M, Van Asselt ADI, Bachmann LM, Kessels AGH, Severens JL. Cost-effectiveness of pharmacogenetic testing to predict treatment response to ACE inhibitor. *Pharmacogenetics and Genomics* 2007; 17: 359-368.
202. Cals JWJ, Hopstaken RM, Butler CC, Hood K, Severens JL, Dinant GJ. Improving management of patients with acute cough by C-reactive protein point of care testing and communication training (IMPAC3T): study protocol of a cluster randomised controlled trial. *BMC Family Practice* 2007, 8:15.
203. Wolfs CAG, Verhey FRJ, Kessels A, Winkens RAG, Severens JL, Dirksen CS. GP-concordance with advice for treatment following a multidisciplinary psychogeriatric assessment. *Int J Geriatr Psych*. 2007; 22; 233-240.
204. Fiddelers AAA, Severens JL, Dirksen CD, Dumoulin JCM, Land JA, Evers JLH. Economic evaluations of single versus double embryo transfer in IVF. *Hum Reprod Update* 2007; 13: 5-13.
205. Willems D, Joore M, Hendriks H, Wouters E, Severens J. The cost-effectiveness of self-management in asthmatics. A systematic review of peak-flow monitoring interventions. *Int J Techn Assessm Health Care*. 2006; 22: 436-442.
206. Martens JD, Van der AA A, Panis B, Van der Weijden T, Winkens RAG, Severens JL. Design and evaluation of a computer reminder system to improve prescribing behaviour of GPs. *Stud Health Technol Inform*. 2006; 124: 617-623.
207. Martens JD, Winkens RAW, Van der Weijden T, De Bruyn DD, Severens JL. Does a joint development and dissemination of multidisciplinary guidelines improve prescribing behaviour: a pre/post study with concurrent control group and a randomised trial. *BMC Health Serv Res* 2006; 6: 145.
208. Welsing PMJ, Severens JL, Hartman M, Gestel AM van, Riel PLCM van, Laan RFJM. The development and validation of a Markov model for the economic evaluation of (new) treatments in rheumatoid arthritis. *Pharmacoeconomics* 2006; 24 (10): 1011-1020.
209. Verkerk K, Van Veenendaal H, Severens JL, Hendriks E, Burgers J. Considered judgement in evidence based guideline development. *Int J Qual Health Care*. 2006;18; 365-369.
210. Fiddelers AAA, Van Montfoort APA, Dirksen CD, Dumoulin JCM, Land JA, Dunselman GAJ, Janssen JM, Severens JL, Evers JLH. Single versus double embryo transfer: cost-effectiveness analysis alongside a randomized clinical trial. *Hum Reprod* 2006; 21 (8): 2090-2097.

211. Wolfs CAG, Dirksen CD, Severens JL, Verhey FRJ. The added value of a multidisciplinary approach in diagnosing dementia: A review. *Int J Geriatr Psychiatry* 2006; 21 (3): 223-232.
212. Brunenberg DEM, Joore MA, Veraart CPWM, Berghmans BCM, van der Vaart CH, Severens JL. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training. *Clin Ther* 2006; 28 (4): 604-618.
213. Berkowitz FE, Severens JL, Blumberg HM: Exposure to tuberculosis among newborns in a nursery: decision analysis for initiation of prophylaxis. *Infect Control Hosp Epidemiol* 2006; 27 (6): 604-611.
214. Van Mastrigt GAPG, Maessen JG, Heijmans J, Severens JL, Prins MH. Does fast track lead to a decrease of intensive care unit and hospital length of stay in coronary artery bypass patients? A meta-regression of randomized clinical trials. *Crit Care Med* 2006; 34 (6): 1624-1634.
215. Kaper J, Wagena EJ, van Schayck CP, Severens JL. The Encouraging smokers to quit; the cost-effectiveness of reimbursing the costs of smoking cessation treatment. *Pharmacoeconomics* 2006; 24 (5): 453-464.
216. Steuten LMG, Vrijhoef HJM, Severens JL, Merode GG van, Spreeuwenberg C. Are we measuring what matters in Health Technology Assessment of disease management? Systematic literature review. *Int J Techn Assessm Health Care* 2006; 22 (1): 47-57.
217. Boonen A, Van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, Van der Linden SJ. Markov model into the cost-utility over five years of TNF- $\alpha$  inhibitors compared to usual care in patients with active ankylosing spondylitis. *Ann Rheum Dis* 2006; 65: 201-208.
218. Van Mastrigt GAPG, Dielen FMH van, Severens JL, Voss GBWE, Greve JW. One-year cost-effectiveness of surgical treatment of morbid obesity: vertical banded gastroplasty versus lap-band. *Obesity Surg* 2006; 16: 75-84.
219. Van Mastrigt GAPG, Heijmans J, Severens JL, Fransen E, Roekaerts P, Voss G, Maessen JG. Short stay intensive care after coronary artery bypass surgery: randomised clinical trial on safety and cost effectiveness. *Crit Care Med* 2006, 34 (1): 65-74.
220. Welsing PMJ, Kievit W, Laan RFJM, Severens JL. Quality of Life and costs for different treatment strategies for active RA. *Expert Rev Pharmacoecon Outcomes Res* 2005; 5; 395-410.
221. Severens JL, Brunenberg DEM, Fenwick EAL, O'Brien B, Joore MA. Cost-effectiveness acceptability curves and a reluctance to lose. *Pharmacoeconomics* 2005; 23 (12): 1207-1214.
222. Knoester PD, Boendermaker AJ, Egberts ACG, Hekster YA, Keyser A, Severens JL, Renier WO, Deckers CLP. Cost-effectiveness of add-on lamotrigine therapy in clinical practice. *Epilepsy Res* 2005; 67: 143-151.
223. Van Velden ME, Severens JL, Novak A. Economic evaluations of healthcare programmes and decision-making; the influence of economic evaluations on different healthcare decision-making levels. *Pharmacoeconomics* 2005; 23: 1075-1082.
224. Boonen A, Severens JL, Van Tubergen A, Landewé R, Van der Heijde D, Van der Linden SJ. The willingness of patients with ankylosing spondylitis to pay for an inpatient treatment is influenced by the treatment environment and improvement expectations. *Ann Rheum Dis* 2005;64: 1650-1652.
225. Lamers LM, Meerding WJ, Severens JL, Brouwer W. The relationship between productivity and health related quality of life: an empirical exploration in persons with low back pain. *Quality of Life Research* 2005; 14: 805-813.
226. Jacob KHM, Koopmanschap MA, Meerding W, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programmes. *Health Econ* 2005; 14: 435-443.
227. Meerding WJ, IJzelenberg H, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. *J Clin Epid.* 2005; 58: 517-523.
228. Brouwer WB, Meerding WJ, Lamers LM, Severens JL. The relationship between productivity and health-related QoL; an exploration. *Pharmacoeconomics* 2005; 23: 209-218.

229. Boonen A, Van den Heuvel R, Van Tubergen A, Goossens M, Severens JL, Van der Heijde D, Van der Linden Sj. Large differences in cost-of-illness and well being between patients with fibromyalgia and chronic low back pain compared to ankylosing spondylitis. *Ann Rheum Dis* 2005; 64: 396-402.
230. Kievit W, Bruin JHFM de, Adang EEMM, Severens JL, Kleibeuker JH, Sijmons RH, Ruers TJ, Nagengast FM, Vasen HFA, Van Krieken HHJM, Ligtenberg MJL, Hoogerbrugge N. Cost-effectiveness of a new strategy to identify HNPCC patients. *Gut* 2005, 54: 97-102.
231. Koopmanschap M, Burdorf A, Jacob K, Meerding WJ. Brouwer W, Severens H. Productivity and health in economic evaluation; setting the research agenda. *Pharmacoeconomics* 2005; 23: 47-54.
232. Fiddelers AAA, Voss G, Land JA, Kessels AGH, Severens JL. Cost-effectiveness of Chlamydia antibody tests in subfertile women. *Hum Reprod* 2005; 20 (2): 425-432.
233. Welsing PMJ, Severens JL, Hartman M, Van Riel PLCM, Laan RFJM. Modeling study into the cost-effectiveness over 5 year of treatment strategies including TNF-blocking treatment and leflunomide treatment in the Netherlands. *Arthritis Care & Research* 2004; 51 (6): 964-973.
234. Flobbe K, Kessels AGH, Severens JL, Beets GL, Koning HJ de, Von Meyenfeldt MF, Engelshoven JMA van. Costs and effects of the use of ultrasonography in the evaluation of palpable breast masses. *Int J Techn Assessm Health Care* 2004; 20: 440-448.
235. Steuten LMG, Vrijhoef HJM, Merode GG van, Severens JL, Spreeuwenberg C. The health technology assessment-disease management instrument reliably measured methodologic quality of health technology assessments of disease management. *J Clin Epid* 2004; 75: 881-888.
236. Boonen A, Severens JL, Van der Linden Sj. A tale of two cities. Comparison of hospitalisation costs in 1897 and 1997. *Int J Techn Assessm Health Care* 2004; 20: 236-241.
237. Hartman M, Ede A van, Severens JL, Laan RFJM, Van de Putte LBA, Van der Wilt GJ. Economic evaluation of folate supplementation during methotrexate in rheumatoid arthritis. *J Rheumatol* 2004; 31: 902-908.
238. Severens JL, Milne RJ. Discounting health outcome in economic evaluation; the ongoing debate. *Value Health* 2004; 7 (4): 397-401.
239. Severens JL, Prins J, Van der Wilt GJ, Meer J van der, Bleijenberg G. Cost effectiveness of cognitive behaviour therapy for patients with chronic fatigue syndrome. *QJM* 2004; 97: 153-161.
240. Konst E, Prah C, Weersink-Braks H, Boo Th de, Prah-Anderson B, Kuijpers-Jagtman AM, Severens JL. Cost-effectiveness of infant orthopedic treatment regarding speech in patients with complete unilateral cleft lip and palate: A randomized three-center trial in the Netherlands (Dutchcleft). *Cleft Palate Craniofac J* 2004; 41: 71-77.
241. Lobo CM, Euser L, Kamp J, Frijling BD, Severens JL, Hulscher MEJL, Grol RPTM, Prins A, Wouden JC van der. Process evaluation of a multifaceted intervention to improve cardiovascular disease prevention in general practice. *Eur J Gen Pract* 2003. 9: 77-83.
242. De la Rosette JJMCH, Floratos DL, Severens JL, Kiemeny LALM, DeBruyne FMJ, Pilar Laguna M. Transurethral resection versus microwave thermotherapy of the prostate: a cost-consequence analysis. *BJU* 2003; 9: 713-718.
243. O'Brien BJ, Spath M, Blackhouse G, Severens JL, Dorian P, Brazier J. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utility Index. *Health Economics* 2003; 12: 975-981.
244. Martens JD, Winkens RAG, Severens JL. Beter antibioticabeleid. *Medisch Contact* 2003, 58 (36). 1345-1347.
245. Boll APM, Severens JL, Verbeek ALM, Vliet JA van der. Mass screening on abdominal aortic aneurism in men aged 60 to 65 years in the Netherlands. Impact on life expectancy and cost-utility using a Markov model. *Eur J Vasc Endovasc Surg* 2003; 26: 74-80.
246. Abraham D, Bronkhorst EM, Truin GJ, Felling A, Severens JL. How dental utilisation in the Netherlands was affected by a radical reform of the dental insurance system. *Comm Dental Health* 2003; 20: 34-39.
247. Bleijenberg G, Prins J, Severens JL, Van der Meer JW. Meer zorg bij beperkt budget; een pleidooi voor een betere inzet van het doelmatigheids criterium. *Ned Tijdschr Gen* 2003; 147: 134.

248. IJzerman M, Reuzel R, Severens JL. Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands. *Int J Techn Assessm Health Care* 2003; 19: 17-27.
249. Severens JL. Value for money of changing health care services? Economic evaluation of quality improvement. *Qual Safe Health Care* 2003; 12: 366-371.
250. Hartman M, Prins M, Swinkels OQJ, Severens JL, Boo Th de, Van der Wilt GJ, Van de Kerkhof PCM, Van der Valk PGM. Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment *Br J Dermatol* 2002; 147: 538-544.
251. Abraham D, Bronkhorst EM, Truin GJ, Severens JL, Felling A. Determining the explanatory potential of variables. *J Dent Res* 2002; 81: 289-294.
252. Boonen A, Severens JL. Ankylosing Spondylitis: What is the cost to society and can it be reduced? *Best Practice & Research Clinical Rheumatology* 2002; 16: 691-705.
253. Oerlemans HM, Oostendorp RAB, Boo ThM de, Severens JL, Zuurmond WWA, Perez RSGM, Goris RJA. Gunstig effect van adjuvante fysiotherapie (en in mindere mate van ergotherapie) vergeleken met maaschappelijk werk bij posttraumatische dystrofie: een gerandomiseerd gecontroleerd klinisch onderzoek. *Ned Tijdschr Gen* 2002; 146: 895-901.
254. Severens JL. Zeker meten. Zeker weten? Medical Technology Assessment als instrument. *Med Contact* 2002; 75: 1356-1359.
255. Severens JL, Habraken JM, Duivenvoorden S, Frederiks CMA. The cost-of-illness of pressure ulcers in the Netherlands. *Adv Skin & Wound Care* 2002; 15: 72-77.
256. Severens JL, Sonke GS, Laheij RJF, Verbeek ALM, De Vries Robbé PF. Efficient diagnostic test sequence: Applications of the probability modifying plot. *J Clin Epid* 2001; 54: 1228-1237.
257. Severens JL. Economic evaluation in health care: the usefulness of research guidelines (guest editorial). *Eur J Obstet Gynaecol Reprod Biol* 2001; 94: 5-7.
258. Hartman M, Rovers MM, Ingels K, Zielhuis GA, Severens JL, Van der Wilt GJ. Economic evaluation of treatment with ventilation tubes compared to watchful waiting in children with persistent otitis media with effusion. *Arch Otoaryngol Head Neck Surg* 2001; 127: 1471-1476.
259. Engelbrecht MR, Jager GJ, Severens JL. Patient selection for magnetic resonance imaging of prostate cancer. *Eur Urol* 2001; 40: 300-307.
260. Van Ede A, Laan RFJM, Rood MJ, Huizinga TWJ, Van der Laar MAFJ, Van Denderen C, Westgeest TAA, Romme TC, De Rooij RAM, Jacobs MJM, De Boo ThM, Van der Wilt GJ, Severens JL, Hartman M, Krabbe PFM, Dijkmans BAC, Breedveld FC, Van de Putte LBA. Effect of folic and folinic acid suppletion on toxicity and efficacy of methotrexate in rheumatoid arthritis. *Arthritis Rheum* 2001; 44: 1515-1524.
261. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, Boo ThM de, Severens JL, Van der Wilt GJ, Spinhoven P, Meer JWM van der. Cognitive behaviour therapy for chronic fatigue syndrome: a multicenter randomised controlled trial. *Lancet* 2001; 357: 841-847.
262. Severens JL, Boo ThM de, Roosmalen MS van, Verweij PE, Van der Wilt GJ. Validity of willingness-to-pay for non-decisional diagnostic information. *Health Econ Prev Care* 2000; 1: 2-8.
263. Severens JL, Habraken JM, Frederiks CMA, Duivenvoorden S. Kosten van decubitus in Nederland; een inventarisatie op basis van expert-opinion. *Woundcare Consultant Society Nieuws* 2000; 16: 20-25.
264. Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in the Netherlands. *Soc Sci Med* 2000; 51: 243-249.
265. Akehurst R, Anderson P, Brazier J, Brennan A, Briggs A, Buxton M, Cairns J, Calvert N, Claxton K, Dixon S, Fryback D, Gallivan S, Green C, Lloyd A, McCabe C, Mitchell A, Nicholl J, O'Brien B, Roberts J, Sculpher M, Severens H, Sullivan S, Veenstra D. Decision analytic modelling in the economic evaluation of health technologies: a consensus statement. *PharmacoEconomics* 2000; 17: 443-444.

266. Jager GJ, Severens JL, Thornbury JR, Oosterhof GON, Ruijs JHJ, Barentsz JO. Prostate cancer staging; is the utilization of MR imaging appropriate? A decision analytic approach. *Radiology* 2000; 215: 445-451.
267. Oerlemans HM, Oostendorp RAB, Boo ThM de, Laan L van der, Severens JL, Goris RJA. Randomised controlled clinical trial of adjuvant physiotherapy versus occupational therapy in patients with reflex sympathetic dystrophy / complex regional pain syndrome I. *Arch Physic Med Rehab* 2000; 81: 49-56.
268. Albers JMC, Kuper HH, Van Riel PLCM, Prevoo MLL, Van 't Hof MA, Van Gestel AM, Severens JL. Socioeconomic consequences of rheumatoid arthritis in the first year of the disease. *Rheumatol* 1999; 38: 423-430.
269. Laheij RJF, Jansen JBMJ, Van de Lisdonk EH, Severens JL, Verbeek ALM. The prognostic value of gastrointestinal morbidity for gastric cancer. *Fam Pract* 1999; 16: 129-132.
270. Severens JL, Oerlemans HM, Weegels AJPG, Van 't Hof MA, Oostendorp RAB, Goris RJA. Cost-effectiveness analysis of adjuvant physical or occupational therapy for patients with reflex sympathetic dystrophy. *Arch Physic Med Rehab* 1999; 80: 1038-1043.
271. Severens JL, De Boo ThM de, Konst EM. Uncertainty of incremental cost-effectiveness ratios: a comparison of Fieller and bootstrap confidence intervals. *Int J Techn Assessm Health Care* 1999; 15: 608-614.
272. Severens JL and Van der Wilt GJ. Economic evaluation of diagnostic tests: a review of published studies. *Int J Techn Assessm Health Care* 1999; 15: 480-496.
273. Severens JL, De Vries Robbé PF, Verbeek ALM. Optimizing diagnostic test sequences: the probability modifying plot. *Meth Inf Med* 1999; 38: 50-55.
274. Laheij RJF, Severens JL, Van de Lisdonk EH, Verbeek ALM, Jansen JBMJ. Randomised controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia; a cost-effectiveness analysis. *Aliment Pharmacol Therap* 1998; 12: 1249-1256.
275. Baltussen RMPM, Wielink G, Stoevelaar HJ, Van der Wilt GJ, Severens JL, Ament AJHA. The economic impact of the introduction of TUMT in the treatment of BPH: a scenario analysis. *World J Urol* 1998; 16: 142-147.
276. Severens JL, Konst EM, Prah C. Principes van kosten-effectiviteitsanalyse bij stem-, spraak- en taalstoornissen. *Stem-, Spraak- en Taalpathologie* 1998; 7: 158-167.
277. Severens JL, Laheij RJF, Jansen JBMJ, Van de Lisdonk EH, Verbeek ALM. Estimating the cost of lost productivity in dyspepsia. *Aliment Pharmacol Therap* 1998; 12: 919-923.
278. Severens JL, Prah C, Kuijpers-Jagtman AM, Prah-Andersen B. Short-term cost-effectiveness analysis of presurgical orthopedic treatment in children with complete unilateral cleft lip and palate. *Cleft Pal Craniofac J* 1998; 35: 222-226.
279. Severens JL, Donnelly JP, Meis JFGM, De Vries Robbé PF, De Pauw BE, Verweij PE. Two strategies for managing invasive aspergillosis: a decision analysis. *Clin Infect Dis* 1997; 25: 1148-1154.
280. Severens JL, Brokx JPL, Van den Broek P, Cost analysis of cochlear implants in deaf children in the Netherlands. *Am J Otol* 1997; 18: 714-718.
281. Laheij RJF, Severens JL, Jansen JBMJ, Van de Lisdonk EH, Verbeek ALM. Management in general practice of patients with persistent dyspepsia; a decision analysis. *J Clin Gastroenterol* 1997; 25: 563-567.
282. Laheij RJF, Jansen JBMJ, Van de Lisdonk EH, Severens JL, Verbeek ALM. Symptom improvement through eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 1996; 10: 843-850.

#### Editorials / Letters

1. Hoomans T, Severens JL. Economic evaluation of implementation strategies in health care. *Implementation Sci* 2014; 9 (1):168. (invited editorial).
2. Hoomans T, Severens JL, van der Roer N, Delwel GO. The authors' reply. *Pharmacoeconomics* 2012; 30 (10): 980. (response to letter to the editor)

3. Severens JL. Loss aversion and cost-effectiveness of health care programmes: whose aversion counts anyway? *PharmacoEconomics* 2008; 26 (11): 899-900. (response to letter to the editor)
4. Verhey FRJ, Wolfs CAG, Kessels A, Dirksen CD, Severens JL. Author's reply to McNulty S et al. Integrated multidisciplinary diagnostic approach for dementia. *Brit J Psych* 11 June 2008. (response to letter to the editor)
5. Verhey FRJ, Wolfs CAG, Kessels A, Dirksen CD, Severens JL. Author's reply to A. Kumar JHA. Integrated multidisciplinary diagnostic approach for dementia care. *Brit J Psych* 25 April 2008. (response to letter to the editor)
6. Verhey FRJ, Wolfs CAG, Kessels A, Dirksen CD, Severens JL. Author's reply to Partridge J, Hill L. Multidisciplinary dementia care: a need for core training. *Brit J Psych* 25 April 2008. (response to letter to the editor)
7. Welsing PMJ, Severens JL, Laan RFJM. Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result. *Rheumatology* 2003. 42 (12). 1574-1575. (letter to the editor)
8. Laheij RJF, Severens JL, Janssen JBMJ. Empirical treatment or prompt endoscopy. *Lancet* 2001; 357: 1366. (letter to the editor)
9. Jager GJ, Severens JL. Diagnostic strategy in uncertainty (letter). *Medical Decision Making* 2000; 20: 355-356.
10. Roosmalen MS van, Severens JL, Meis JFGM, Lees E, Barton R, Verweij PE. Prevalence of antibodies to *Histoplasma capsulatum* among Dutch speleologists (letter). *J Infect* 1998; 37: 200-201.
11. Laheij RJF, Severens JL, Verbeek ALM, Jansen JBMJ. Cost effectiveness of treatment for gastrooesophageal reflux disease (letter). *Gut* 1998; 43: 728-729.
12. Laheij RJF, Severens JL. Cost of endoscopy in economic evaluation (letter). *Gastroenterol* 1997; 113: 223-224.

#### Book chapters and reports

- Severens JL, Hoomans T, Adang E, Wensing M. Economic evaluation of implementation strategies. In: Wensing M, Grol R, Grimshaw J. (eds) *Improving Patient Care: The Implementation of Change in Health Care*, Third Edition. John Wiley Blackwell Ltd, 2020.
- Van Baal P, Thongkong N, Severens JL. Human resource constraints and the methods of economic evaluation of health care technologies. Rotterdam: iBMG, 2015.
- Luyendijk M, Hoogendoorn M, Severens JL. Cost-effectiveness of a treat-to-target strategy in patients with early rheumatoid arthritis. Rotterdam: iBMG, 2015.
- Buyukaramikli NC, Leunis A, Severens JL. Pharmaco-economic evaluation of liposomal amphotericin B (AmBisome®) for the treatment of severe systemic fungal infections in the Netherlands. Rotterdam: iBMG, 2015.
- Leunis A, Buyukaramikli NC, Severens JL. Outcomes research of liposomal amphotericin B (AmBisome®) for the treatment of severe systemic fungal infections in the Netherlands. Rotterdam: iBMG, 2015.
- Severens JL, Chitama D, Van Rijsbergen B. ORET Evaluation 2007-2012 – Case Study of the ORET Transaction TZ00030; Making Things Better: Rehabilitating Diagnostic Services in Tanzania. The Hague 2015.
- Van der Windt N, Severens JL, Chitama D. Final evaluation report. Rehabilitation of diagnostic services in Tanzania (TZ00030), ORET Evaluation 2007-2012. Rotterdam 2014.
- Severens JL. Mission report project visit. "ORET Evaluation 2007-2012; Rehabilitation of Diagnostic Services in Tanzania" a transaction executed by Philips Medical Systems (TZ00030). Rotterdam 2014.
- Severens JL, Hoomans T, Adang E, Wensing M. Economic evaluation of implementation strategies. In: Grol R, Wensing M, Eccles M, Davis D. (eds) *Improving Patient Care: The Implementation of Change in Health Care*, Second Edition. John Wiley & Sons, Ltd, 2013.
- Gaultney JP, Severens JL, Uyl-de Groot CA. Outcomes Research and Pharmacoeconomic Evaluation of amphotericin B (AmBisome®) for the Treatment of Severe Systemic Fungal Infections in the Netherlands. Rotterdam: iBMG, 2013.

- Severens JL, Majoor GD. Final evaluation report. Project NPT-YEM-259: 'Support strengthening the institutional and educational capacity to deliver qualified graduates in medical sciences applying the Problem Based Learning (PBL) approach, focusing on the clinical phase' executed by Hadhramout University College of Medicine (HUCOM) Al Mukalla, Yemen in collaboration with Maastricht University, MUNDO Maastricht, the Netherlands. Rotterdam, 2013.
- Postma M, DeWit A, Severens JL. Economische evaluatie studies van publieke gezondheidszorg. In: Van Lienden HW, Boot JMD (eds), *Economie van de gezondheid*, Koninklijke Van Gorcum, Assen, 2011.
- Westwood M, Al MJ, Burgers LT, Redekop WK, Lhachimi SK, Armstrong N, Raatz H, Misso K, Severens JL, Kleijnen J. Computed tomography (CT) scanners for cardiac imaging – Somatom Definition Flash, Aquilion One, Brilliance iCT and Discovery CT750 HD: a Diagnostic Assessment Report. York: Kleijnen Systematic Reviews Ltd., 2011.
- Riemsma R, Lhachimi SK, Armstrong N, Van Asselt, ADI, Allen A, Manning N, Harker J, Tushabe DA, Severens JL, Kleijnen J. Roflumilast for the management of severe chronic obstructive pulmonary disease: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd., 2011.
- Riemsma R, Joore MA, Grutters JPC, Armstrong N, Misso K, Noake C, Tushabe DA, Severens JL, Kleijnen J. Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd, 2011.
- Riemsma R, Al MJ, Lhachimi SK, Armstrong N, Misso K, Manning N, Lang S, Severens JL, Kleijnen J. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd., 2011.
- Riemsma R, Al MJ, Armstrong N, Misso K, Allen A, Manning N, Tushabe DA, Severens JL, Kleijnen J. Mannitol dry powder for inhalation for the treatment of cystic fibrosis: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd., 2011.
- Severens JL. End of term evaluation report; Support to the development of Faculties of Medicine, Project NPT/ETH 107 executed by College of Health Sciences, Mekele University, Mekele, Tigray, Ethiopia and College of Medicine & Health Sciences, Hawassa University, Hawassa, Southern Nations Nationalities' and Peoples' Regional State, Ethiopia in collaboration with Maastricht University, MUNDO, Maastricht, The Netherlands. Rotterdam 2010.
- De Kinderen RJA, Oberjé EJM, Severens JL, Ament AJHA. An update of the economic evaluation of pre-emptive treatments of invasive aspergillosis in adult bone marrow transplant recipients in the Netherlands, Maastricht UMC, 2010.
- Majoor GD, Severens JL. Midterm evaluation report. Project NPT-YEM-259: 'Support strengthening the institutional and educational capacity to deliver qualified graduates in medical sciences applying the Problem Based Learning (PBL) approach, focusing on the clinical phase' executed by Hadhramout University College of Medicine (HUCOM) Al Mukalla, Yemen in collaboration with Maastricht University, MUNDO Maastricht, the Netherlands. Sana'a-Maastricht, 2009.
- Winkens R, Van der Weijden T, Severens H, Jan Dinant GJ. Improving test ordering and its diagnostic cost-effectiveness in clinical practice—bridging the gap between clinical research and routine health care. In: Knottnerus JA and Buntinx F (eds). *The evidence base of clinical diagnosis: theory and methods of diagnostic research*, Second Edition. Wiley-Blackwell, Oxford, UK 2009.
- Reda AA, Kaper J, Fikrelter H, Severens JL, Van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD004305. The Cochrane Collaboration. John Wiley & Sons, Ltd.
- Goebbels A, Ament A, Severens JL Economic evaluation of alternative cholesterol-lowering strategies in patients with varying LDL-c baseline values, BEOZ, CAPHRI, 2007
- Franke A, Severens JL, Ament A. Economic consequences of rheumatoid arthritis and ankylosing spondylitis: a survey of literature. BEOZ, CAPHRI, 2007
- Goebbels A, Severens JL, Ament A. Estimating the implicit value of statistical life in different societal sectors in the Netherlands. BEOZ, CAPHRI, 2007

- Severens JL, Wensing M. Economische evaluatie van implementatiestrategieën. In: Grol R, Wensing M (eds). Implementatie; effectieve verbetering van de patiëntenzorg. 3<sup>e</sup> druk. Elsevier Gezondheidszorg, Maarssen 2006.
- Kaper J, Wagena EJ, Severens JL, Van Schayck CP. Healthcare financing systems for increasing the use of tobacco dependence treatment. The Cochrane Collaboration. John Wiley & Sons, Ltd. 2005.
- Severens JL, Martens JD, Wensing M. Economic evaluation of implementation strategies. In: Grol R, Wensing M, Eccles M. Improving patient care. The implementation of change in clinical practice. Elsevier Butterworth Heinemann, London 2005.
- Severens JL. Value for money of changing healthcare services? Economic evaluation of quality improvement. In: Grol R, Baker R, Moss F. Quality Improvement Research: Understanding the science of change in health care. BMJ Publishing Group, London 2003.
- Severens JL, Janszen AJMD, Delwel GO. Pharmaceconomic dossier assessment form. College voor zorgverzekeringen, Amstelveen 2002.
- Severens JL, Economische evaluaties en evidence based medicine. In: Berden HJJM, Heyden JTM van der, Hubben JH, Roex AJM. Vraagbaak Medisch Specialist. Bohn stafleu Van Loghum, Houten 2001 (in Dutch).
- Severens JL, Wensing M. Economische evaluaties van implementatie strategieën. In: Grol R, Wensing M. Implementatie; effectieve verandering in de patiëntenzorg. Elsevier gezondheidszorg, Maarssen 2001 (in Dutch).
- Severens JL. A cost of illness study of pressure ulcers in the Netherlands. Dept. of MTA, University Medical Centre St. Radboud, Nijmegen. 1999 (in Dutch).
- Bleijenberg G, Prins J et al. Cognitive behaviour therapy for patients with chronic fatigue syndrome. Dept. of Medical Psychology. University Medical Centre St. Radboud, Nijmegen. 1999 (in Dutch).
- Klein-Rouweler EH, Bleijenberg G, Severens JL. Prevalance of chronic fatigue syndrome in the Netherlands. Dept. of Medical Psychology. University Medical Centre St. Radboud, Nijmegen. 1999 (in Dutch).
- Kuijpers-Jagtman AM, Konst EM, Prah C, Severens JL. A multicentre prospective clinical trial into the effects of presurgical infant orthopedics in children with a complete UCLP. Second report. Dept of Orthodontics and Orla Biology, University Medical Centre St. Radboud, Nijmegen, Monitoring Committee Clinical Trial PSOT. 1998.
- Severens JL, Prah C. Cost-effectiveness analysis. In: Kuijpers-Jagtman AM, Prah C. A study into the effects of presurgical orthopaedic treatment in complete unilateral cleft lip and palate patients: interim analysis. University Medical Centre St. Radboud, Nijmegen 1996. pp. 51-59.
- Severens JL. Kostenanalyse. In: Broek P van den. Eindverslag van het ontwikkelingsgeneeskunde projekt Cochleaire Implantatie bij kinderen. Dept of ENT, University Medical Centre St. Radboud, Nijmegen 1996; pp. 97-103 (in Dutch).
- Beckers WPA, Severens JL Vries Robbé PF de. Topreferentie Academische Ziekenhuizen: rapportage pilotstudie. Dept of Medical Informatics, University Medical Centre St. Radboud, Nijmegen 1993 (in Dutch).

#### Abstracts (published)

<<to be completed xxx>>

- Buyukkaramikli N, Van Agthoven M, Leunis A, Severens JL. Economic evaluation of targeted antifungal treatment sequencing strategies for invasive aspergillosis based on real world data: the case of Dutch clinical practice. Value Health 2015; 18 (7): A586.
- Grustam AS, Severens JL, De Massari D, et al. The cost-effectiveness analysis of Philips Motiva Telehealth System: a comparison between home telemonitoring, nurse telephone support and usual care in chronic heart failure. Value Health 2015; 18 (7): A559.
- Thongkong N, van Baal P, Severens JL. Including human resource constraints in health economic evaluations. Value Health 2015; 18 (7): A688.

- Tran-Duy A, Boonen A, Caro JJ, Van der Laar M, Severens JL. Implementation of population dynamics in modelling health and budget impact of an intervention for a chronic disease with multiple disease subtypes. *Value Health* 2015; 18 (7): A700.
- Knies S, Boonen A, Severens JL. Do the US-panel recommendations hold for Europe? Investigating the relation between quality of life versus work-status, absenteeism, and presenteeism. *Value Health* 2014; 17 (7): A549-A549.
- Mandrik O, Knies S, Kalo Z et al. Transferability of economic evaluations to central European and eastern European and former Soviet countries. *Value Health* 2014; 17 (7): A443-A444.
- Ramaeker BLT, Armstrong N, Joore MA et al. Cost-effectiveness of high-sensitive troponin assays for the early rule-out or diagnosis of acute myocardial infarction (AMI) in people with acute chest pain: a NICE diagnostic assessment. *Value Health* 2014; 17 (7): A490-A490.
- Buyukkaramikli, N. C.; Gaultney, J.; Leunis, A.; et al. Literature review of decision-analytic models used in the economic evaluation of empirical/targeted antifungal treatment for invasive fungal infections. *Value Health* 2014; 17 (7): A636-A636.
- Bouwmans, C.; Krol, M.; Brouwer, W.; et al. IMTA Productivity Cost Questionnaire (IPCQ). *Value Health* 2014; 17 (7): A588-A588.
- Burgers LT, Redekop WK, Severens JL. Decision analytic models used in estimating the cost-effectiveness of drug-eluting-stents versus bare-metal-stents: a systematic review. *Value Health* 2013; 16 (7):
- Burgers LT, Redekop WK, Severens JL. Challenges in modelling the cost-effectiveness of interventions in cardiovascular disease. *Value Health* 2013; 16 (7): A327-A327.
- Frederix GW, Severens JL, Hovels AM, et al. Time dependant resource use and costs associated with different states of disease in patients diagnosed with HER-2 positive metastatic breast cancer. *Value Health* 2013; 16 (7): A578- A578.
- Vaidya A, Joore MA, Ten Cate-Hoek AJ, et al. Screen or not to screen for peripheral arterial disease : guidance from a decision model. *Value Health* 2013; 16 (7): A528-A528.
- Van Haalen HGM, Tran-Duy A, Boonen A, Severens JL. How to select the right cost-effectiveness model? A systematic review and stepwise approach for transferring an existing health economic model for rheumatoid arthritis. *Value Health* 2013; 16 (7): A590-A590.
- Tran-Duy A, Boonen A, Kievit W, Van Riel PLCM, Van de Laar MAFJ, Severens JL. Comparison of the cost-effectiveness of the treatment strategies with and without biological response modifiers for patients with recently diagnosed rheumatoid arthritis following a clinical guideline for treatment selection. *Arthritis Rheumatism* 2013; 65 (suppl 10): S427-S427.
- Frederix GWJ, Van Hasselt JGC, Severens JL, Hovels AM, Huitema ADR, Raaijmakers JAM, Schellens JHM. Development of a continuous-time markov model and evaluation of the impact of cycle length and time horizon. *Br J Clin Pharmacol* 2013; 76 (5): 832-832.
- Deshpande S, Westwood M, van Asselt ADI, Armstrong N, Tomini F, Allen A, Noake C, Khan K, Severens JL, Kleijnen J. Combining trial and accuracy data for diagnostic tests : a systematic review of fetal fibronectin (fFN) testing to predict preterm birth. Poster presented at HTAi Annual Meeting; 25-27 Jun 2012; Bilbao, Spain. 2012.
- Benning T, Dellaert B, Severens J, Dirksen CD. Does presenting follow-up test information affect peoples' preferences for colorectal cancer screening tests?; a discrete choice experiment. *Value Health* 2012; 15 (7): A358-A358.
- Burgers LT, Nauta ST, Deckers JW, Severens JL, Redekop WK. Is it worth spending any money to develop a biomarker test to optimize statin treatment for individuals with an intermediate cardiovascular risk? *Value Health* 2012; 15 (7): A281-A281.
- Frederix GW, Van Hasselt JG, Severens JL, Hovels A, Schellens JH. Development of a framework for cost-effectiveness analysis cohort simulation using an ordinary differential equation solver algorithm in R. *Value Health* 2012; 15 (7): A468-A468.

- Frederix GW, Van Hasselt JG, Schellens JH, Hovels A, Severens JL. Impact of structural assumptions on cost-effectiveness outcomes: towards a standardized cost-effectiveness model for adjuvant breast cancer therapies. *Value Health* 2012; 15 (7): A282-A282.
- Hoomans T, Severens JL, Van der Roer N, Delwel G. Is There a Role for Pharmacoeconomics in Decision Making? (Reply). *Pharmacoecon* 2012; 30 (10): 980-980.
- Mandrik O, Zalis'ka O, Severens J. How much price component is accounted for in state drug purchase decisions in Ukrainian oncology? *Value Health* 2012; 15 (7): A428-A428.
- Tran-Duy A, Boonen A, van de Laar M, Severens J. Simultaneous modeling health impact, budget impact and cost-effectiveness in the context of population dynamics: the case of TNF antagonists for ankylosing spondylitis. *Clin Exp Rheumatol*. 2012; 40(4): 608 (SO10).
- Mandrik O, Severens JL, Zalis'ka O, Doroshenko O, Maynych Y, Tolubaiev V. Analysis of factors influencing drug prescription decision making in Ukraine. *Value Health* 2012; 15 (4): A28-A28.
- Mandrik O, Zalis'ka O, Severens JL. Cost-effectiveness analysis of rituximab use in treatment of chronic lymphocytic leukemia in Ukraine. *Value Health* 2012; 15 (4): A221-A221.
- Burgers LT, Redekop W, Westwood M, Lhachimi S, Severens JL, Armstrong N, Sculpher MJ, Walker S, McKenna C, Al M. Using five existing models to comprehensively model the cost-effectiveness of a high definition CT scanner in a coronary artery disease population: a NICE diagnostic guidance project. *Value Health* 2011; 14 (7): A259-A259.
- Burgers LT, Redekop W, Severens JL. Decision analytic models used in estimating the cost-effectiveness of drug-eluting stents versus bare metal stents. *Value Health* 2011; 14 (7): A259-A259.
- Joore MA, Dellaert B, Spijkers L, et al. Outcomes beyond health. *Value Health* 2011; 14 (7): A243-A243.
- Mandrik O, Zalis'ka O, Severens JL. Cost of treatment of multiple myeloma in Ukraine. *Value Health* 2011; 14 (7): A444-A444.
- Handels R, Verhey F, Wolfs C et al. Determinants of care costs of patients with dementia or cognitive impairment. *Int Psychogeriatr* 2011; 23 (suppl. 1): S297-S297.
- Wolfs C, Kessels A, Severens J et al. Predictive factors for the objective burden of informal care in people with dementia: A systematic review. *Int Psychogeriatr* 2011; 23 (suppl. 1): S185-S186.
- Gerhards SAH, De Graaf LE, Jacobs LE, Severens JL, Huibers MJH, Arntz A, Riper H, Widdershoven G, Metsemakers JFM, Evers SMAA. Economic evaluation of online computerized cognitive behavioural therapy without support for depression in primary care: a randomized trial. *J Mental Health Pol Econ*. 2011; S7-S7.
- Wyers CE, Breedveld-Peters JJJ, Reijnen PLM, Helden S van, Guldmond NA, Severens JL, Verburg AD, Meesters B, Rhijn LW van, Dagnelie PC. Designing an RCT to assess the effectiveness of a nutritional intervention after hip surgery. *Focus Altern Compl Therap* 2011; 16, 80-81.
- Tran Duy A, Boonen A, Arsenijevic J, Severens J. Cost-effectiveness of treatment strategies for ankylosing spondylitis: first results of a discrete event simulation model. *Value Health* 2010; 13 (7): A243-244.
- Albers-Heitner P, Joore M, Winkens R, LAgro-Jansen T, Severens J, Berghmans B. Cost-effectiveness of involving nurse specialists for adult patients with urinary incontinence in primary care: an economic evaluation alongside a pragmatic randomized controlled trial based on generic health related quality of life and urinary incontinence specific outcomes. *Int Urogynecol J* 2010; 21 (suppl. 1): S240-S241.
- Scholtissen S, Bruyere O, Neuprez A, Severens H, Herrero-Beaumont G, Rovati L, Hiligsmann M, Reginster J. Cost-effectiveness of glucosamine sulfate compared to acetaminophen in the treatment of knee osteoarthritis: a French health care perspective. *Osteopor Int* 2010; 21 (Suppl.1): 167-167.
- Tran Duy A, Boonen A, Ament A, Landewe R, Severens JL. Mapping measures of disease to the EQ5-D in patients with ankylosing spondylitis: which approach and which instruments fit best? *Clin Experiment Rheumatol* 2010; 28 (4): 613-613.

- Hoomans T, Roer NVD, Severens JL, Delwel G. Cost-effective pharmaceutical care in the Netherlands? A review of the pharmacoeconomics and its role in the assessment and reimbursement of new drugs. *Value Health* 2009; 12: A241
- Hoomans T, Severens JL, Ament, Evers S. Addressing decisions about clinical guidance and its active implementation: sequential or integral analysis? An application in metastatic hormone refractory prostate cancer. *Value Health* 2009; 12: A285.
- Boonen A, Brinkhuizen T, Severens H, Landewe R, Van der Linden SJ. Sick leave, presenteeism and loss of unpaid production in patients with ankylosing spondylitis: Impact and estimation of the societal cost. *Clin Experiment Rheumatol* 2008; 26 (4): 740-740.
- Joore MA, Heijnen VT, Severens JL, Novak A, Oron U, Pompen M, Essers BA. Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. *Value Health* 2008; 11 (6): A347-A347.
- Grutters JP, Pijls-Johannesma M, De Ruyscher D, Dekker AL, Peeters A, Severens JL, Lambin P, Joore MA. Modeling the cost-effectiveness of a new and expensive treatment modality in lung cancer: the case of particle therapy. *Value Health* 2008; 11 (6): A357-A358.
- Spijkers CJ, Dirksen CD, Krabbe PFM, Dellaert BGC, Severens JL, Sommer A, Joore MA. Treatments for varicose vein disease: expectations and experiences of patients. *Value Health* 2008; 11 (6): A412-A412.
- Essers BA, Tjan HV, Severens JL, Novak A, Oron U, Pompen M, Joore MA. Economic evaluation of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands. *Value Health* 2008; 11 (6): A472-A472.
- Peeters A, Joore MA, Pijls-Johannesma M, De Ruyscher D, Dekker AL, Grutters JP, Reimoser S, Severens JL, Lambin P. Modeling the cost-effectiveness of prostate cancer treatment with particle therapy. *Value Health* 2008; 11 (6): A473-A473.
- Peeters A, Grutters JP, Pijls-Johannesma M, Reimoser S, Severens JL, Lambin P, Joore MA. How costly is radiotherapy with particles? Cost-analysis of external beam radiotherapy with carbon ions, protons and conventional photons. *Value Health* 2008; 11 (6): A480-A480.
- Hoomans T, Abrams K, Evers SMAA, Ament AJHA, Severens JL. Modelling the value for money of clinical practice change: a stochastic application in diabetes care. *Value Health* 2008; 11 (6): A562-A563.
- Knies S, Evers SMAA, Severens JL, Candel MJJM, Ament AJHA. Utilities of the EQ-5D: transferable or not? Influence of the national value sets of the EQ-5D on the incremental utilities of two health states. *Value Health* 2008; 11 (6): A575-A575.
- Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of economic evaluations. Validating the model of Welte. *Value Health* 2008; 11 (6): A576-A576.
- Goebbels AFG, Ament AJHA, Novak A, Veraart CPWM, Severens JL. The implicit value of statistical life: estimates derived from public interventions implemented in the Netherlands. *Value Health* 2008; 11 (6): A578-578.
- Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Stochastic application of model for informing resource allocation decision making about the implementation of clinical practice guidelines in diabetes care. HESG 2007, Norwich, UK (paper and presentation), 2007.
- Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Worthwhile implementation of evidence-based guidelines into clinical practice: how to determine the investment potential for guideline implementation and the value for money of implementation strategies? IHEA 2007, Copenhagen, Denmark (abstract and presentation), 2007.
- Kroese MEAL, Schulpen GJC, Bessems-Beks MCM, Severens HL, Nijhuis FJ, Landewe RB. Is it feasible for a specialised rheumatology nurse to (partially) substitute rheumatologists in the diagnostic process of fibromyalgia? A randomised study. *Ann Rheum Dis* 2007; 66 (Suppl.66): 423-423.
- Hoomans T, Ament AJHA, Evers SMAA, Severens JL. Economic decision modelling: calculation of the total net monetary benefits of guideline implementation into clinical practice. Proceedings of ISPOR 9th Annual European Congress 2006.

- Van Dielen FHM, Severens JS, Voss GBWE et al. One-year cost-effectiveness of surgical treatment of morbid obesity: Vertical banded gastroplasty versus Lap-Band. *Obesity Surg* 2005; 15: 943.
- Peeters A, Schouten J, Webers C, Severens J, Hendrikse F, Prins M. The cost-effectiveness of different case-finding strategies for detection and treatment of ocular hypertension and primary open-angle glaucoma by the ophthalmologist. *Value Health* 2005; 8 (3): 368.
- Severens JL, Koopmanschap MA, Meerding WJ. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programs. *Value Health* 2004; 7: 640.
- Van Mastrigt G, Severens H, Heijmans J, Roekaerts P, Voss G, Maessen J. The need for more efficient use of existing intensive care capacity: Is short stay IC for CABG-patients the solution? *Chest* 2004; 126 (4, suppl S): 856S-856S.
- Van Mastrigt G, Severens JL, Heijmans J, Roekaerts P, Voss G, Maessen J. The need for more efficient use of IC capacity: Is short-stay intensive care for CABG patients the solution? *Circulation* 2004; 110 (17, suppl S): 825-825.
- Koopmanschap MA, Meerding WJ, Evers S, Severens JL, Burdorf A, Brouwer WB. PRODISQ, a modular questionnaire on productivity and disease for economic evaluation studies in patient settings and organisational settings. *Value Health* 2004; 7: 644-645.
- Severens JL, Prins MH, Monteban HC. Cost-effectiveness of Astorvastatin compared to Simvastatin in The Netherlands. *Value Health* 2003; 6: 671.
- Van Asselt ADI, Dirksen CD, Severens JL, Arntz A. Production losses in borderline personality disorder: shortcomings in the standard methods of valuation. *Value Health* 2003; 6: 692-693.
- Guhl A, Severens JL. Health economic impact and awareness of psoriasis in Europe. *JEADV* 2003; 17 (suppl. 1): 37.
- Van Asselt ADI, Dirksen CD, Severens JL, Arntz A. Bottom-up or top-down? Impact of patient selection on cost-of-illness results. *Value Health* 2002; 5: 516-516.
- Welsing PMJ, Severens JL, Hartman M, van Riel PLC, Laan RFJ. Modeling study into the cost-effectiveness over 5 year of treatment strategies including TNF-blocking treatment and leflunomide treatment in the Netherlands. *Arthreumat* 2002; 46: S91.
- Abraham D, Bronkhorst EM, Truin GJ, Felling A, Severens JL. Beleidsevaluatie van de stelselwijziging tandheelkunde 1995. *Tijdschrift voor Gezondheidswetenschappen* 2002.
- Bronkhorst E, Abraham EA, Truin GJ, Severens JL, Felling AJA. Modelling dental utilisation in The Netherlands using the PEN-model. *J Dent Res* 2002; 81 (S1): A266-A266.
- Severens JL, Verweij PE, Donnelly JP, Meis JFGM. Cost-effectiveness of liposomal amphotericin B for the treatment of fever of unknown origin in bone marrow transplant patients: a decision analysis. *Eur J Cancer* 2000; 36 (suppl. 3): S6.
- Boll APM, Vliet JA van der, Severens JL. Screening for abdominal aortic aneurism: a Markov model. *Cardiovasc Surg* 2001 (suppl.); 36.
- Jager GJ, Severens JL, Rosette JJMCH de la, Ruijs HJ, Barentz JO. How to determine the cost-effectiveness of MR imaging in pelvic disease. *ESMRMB'99*.
- Laheij RJF, Severens JL, Lisdonk EH van de, Verbeek ALM, Jansen JBMJ. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. *Gastroenterol* 1998; 114 (suppl. 4): G0785.
- Laheij RJF, Severens JL, Lisdonk EH van de, Verbeek ALM, Jansen JBMJ. Disease management of patients with persistent dyspepsia. *Gut* 1997; 41 (suppl. 3) A22.
- Laheij RJF, Severens JL, Lisdonk EH van de, Verbeek ALM, Jansen JBMJ. Disease management of patients with persistent dyspepsia. *Gastroenterol* 1997; 112 (suppl. 4) A3567.
- Verweij PE, Severens JL, Donnelly JP, Vries Robbé PF de, Pauw BE de, Meis JFGM. Een besliskundige analyse van twee strategieën voor de diagnostiek en therapie van invasieve aspergillose. *Ned Tijdschr Med Microbiol* 1997; 5 (suppl.): S20.

Presentations at scientific meetings (overview not complete)

- Kroese MEAL, Robert B.M. Landewé RBM, Schulpen GJC, Bessems MCM, Severens JL. Diagnosis of fibromyalgia is associated with impaired health outcomes and substantial health care costs after 9 months of follow-up. EULAR Madrid, June 2013.
- Sohan Deshpande, Marie Westwood, Antoinette D.I. van Asselt, Nigel Armstrong, Florian Tomini, Alexander Allen, Caro Noake, Khalid Khan, J.L.(Hans) Severens, Jos Kleijnen presented the poster titled "Combining Trial And Accuracy Data For Diagnostic Tests: A Systematic Review Of Fetal Fibronectin (Ffn) Testing To Predict Preterm Birth." at the "9th HTAi Annual Meeting. HTA in Integrated Care for a Patient Centered System" held at the Euskalduna Conference Centre in Bilbao from 23 to 27 June 2012.
- Benning TM, Dellaert BGC, Diksen C, Severens JL. Does Presenting Colonoscopy Information Affect People's Preferences for Colorectal Cancer Screening Tests? A Discrete Choice Experiment, CTMM Annual meeting, September 26 2012, Utrecht, the Netherlands (poster).
- Van Gestel A, Grutters J, Joore M, Severens J, Schouten J, Webers C, Beckers H. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. International Health Economics Associations (iHEA) conference, Oral presentation in the organized session "Every person is unique; heterogeneity in economic evaluation and decision-making". July 2011, Toronto, Canada.
- Van Gestel A, Grutters J, Joore M, Severens J, Schouten J, Webers C, Beckers H. Exploring the role of the expected value of individualized care in cost-effectiveness analyses and decision making. Lowlands Health Economists Study Group conference. May 27-28 2010, Egmond aan Zee, the Netherlands.
- Van Gestel A, Schouten J, Webers C, Beckers H, Jansonius N, Severens J. Construction and validation of a decision analytic model for ocular hypertension and glaucoma. European Glaucoma Society conference, Health Economics Special interest group session. Oral presentation and discussion. 17 September 2010, Madrid, Spain.
- Van Gestel A, Schouten J, Webers C, Beckers H, Jansonius N, Severens J. Validatie van een OHT-POAG ziekteprogressie model. Nederlands Oogheelkundig Gezelschap, Oral presentation. 26 March 2009, Groningen, the Netherlands.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. A novel approach to establish at which IOP to start treatment for ocular hypertension. World Glaucoma Congress,. Poster presentation. 8-11 July 2009, Boston, USA.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Does every bit of visual field loss count? World Glaucoma Congress, 8-11 July 2009, Boston, USA. Poster presentation.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Kwaliteit van leven bij oculaire hypertensie en glaucoom. Nederlands Oogheelkundig Gezelschap, 3 April 2008, Maastricht, the Netherlands. Oral presentation.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Risk of blindness in patients with ocular hypertension. Joint Congress of SOE/AAO, 9-12 June 2007, Vienna, Austria. Rapid Fire Presentation
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Primary open-angle glaucoma: the impact on quality-of-life and utility. Joint Congress of SOE/AAO, 9-12 June 2007, Vienna, Austria. Poster presentation and oral presentation at Best Poster Session.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Een discrete event model voor oculaire hypertensie en glaucoom: concept, opbouw en eerste resultaten. Nederlandse Glaucoom Groep, 11 November 2007, Utrecht, the Netherlands.
- Van Gestel A, Schouten J, Webers C, Beckers H, Severens J. Health related quality of life and utility in Dutch glaucoma patients. European Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 29-31 October 2006, Copenhagen, Denmark. Poster presentation.
- Grutters JPC, Pijls-Johannesma M, Joore MA, De Ruyscher D, Dekker ALAJ, Peeters A, Reimoser S, Severens JL, Lambin Ph. Particle therapy appears to be a cost-effective treatment modality as opposed to conventional 3D radiotherapy and stereotactic body radiotherapy for inoperable stage I non-small cell lung cancer patients, but

- more evidence is needed. Oral presentation. , European Society for Therapeutic Radiology and Oncology Conference, Göteborg, Sweden, September 14-18, 2008.
- Grutters JPC, Peeters A, Joore MA, Pijls-Johannesma M, De Ruyscher D, Dekker ALA, Severens JL, Lambin Ph. Modeling the cost-effectiveness of proton and carbon-ion treatment for lung and prostate cancer: do we need more evidence? Poster presentation. , Particle Therapy Co-Operative Group meeting, Jacksonville, Florida, United States. May 19-24, 2008.
- Grutters JPC, Pijls-Johannesma M, De Ruysche D, Dekker ALAJ, Peeters A, Severens JL, Lambin Ph, Joore MA. Modeling the cost-effectiveness of a new and expensive treatment modality in lung cancer: the case of particle therapy. Oral presentation, International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece. November 8-11, 2008.
- Hoomans T, Severens JL, Evers SMAA, Ament AJHA. Value for money of clinical practice change: should decisions about guidelines and implementation strategies be made sequentially or simultaneously? Health Economists Study Group meeting, University of East Anglia, United Kingdom. 2008.
- Knies S, Evers SMAA, Severens JL, Candel MJJM, Ament AJHA. Utilities of the eq-5d: transferable or not? Influence of the national value sets of the EQ-5d on the incremental utilities of two health states. ISPOR Eleventh Annual European Congress Athens, Greece, 2008. Value Health 2008; 11 (6): A575.
- Knies S, Severens JL, Ament AJHA, Evers SMAA. The transferability of economic evaluations. Validating the model of Welte. ISPOR Eleventh Annual European Congress Athens, Greece, 2008. Value Health 2008; 11(6): A576.
- Peeters A, Joore MA, Pijls-Johannesma M, De Ruyscher D, Dekker ALAJ, Grutters JPC, Reimoser S, Severens JL, Lambin P. ESTRO conference, Goteborg, Sweden. September 14-18, 2008.
- Severens JL. ISPOR transferability of economic data task force forum. 10<sup>th</sup> Annual European Congress, Dublin, Ireland. October 20-23, 2007.
- Severens JL. Conditional reimbursement for hospital based drugs in The Netherlands: policy measure, cost-effectiveness criterium, future oucomes research, methodological and clinical challenges. ISPOR 10<sup>th</sup> Annual European Congress, Dublin, Ireland. October 20-23, 2007.
- Smeets RJEM, Knottnerus JA, Beelen S, Vlaeyen JWS, Severens JL. Cost-effectiveness of three model-based treatment for non-specific chronic disabling low back pain. Palma International Forum IX, Primary Care Research on Low Back Pain, Palma de Mallorca. October 4-6, 2007.
- Smeets RJEM, Knottnerus JA, Beelen S, Vlaeyen JWS, Severens JL. Cost-effectiveness of three model-based treatments for non-specific chronic disabling low back pain. American Academy of Pain Management Annual Meeting , Las Vegas, USA. September 27-30, 2007.
- Van Asselt T, Van Mastrigt G, Kessels A, Dirksen C, Arntz A, Severens H. How to deal with baseline cost differences in cost-effectiveness analyses? International Health Economics Association, Barcelona, Spain. July 10-13, 2005 (poster).
- Van Asselt T, Severens H, Dirksen C, Arntz A. Difficulties in calculating productivity costs for patients with borderline personality disorder. International Health Economics Association, Barcelona, Spain. July 10-13, 2005.
- Evers S, Severens H, Jacob-Tackken K, Koopmanschap M, Meerding W-J. Correcting for compensating mechanisms related to productivity costs in economic evaluations of health care programs. International Health Economics Association, Barcelona, Spain. July 10-13, 2005.
- Van Mastrigt G, Van Asselt T, Kessels A, Maessen J, Severens J. How to deal with baseline utility differences in empirical cost-effectiveness calculations? International Health Economics Association, Barcelona, Spain. July 10-13, 2005 (poster).
- Van\_Mastrigt GAPG, Severens JL, Heymans J, Voss G, Maessen JG. The need for more efficient use of IC Capacity: is Short Stay Intensive Care for CABG-patients the solution? American Heart Association, New Orleans, United States. November 7-10, 2004.
- Van\_Mastrigt GAPG, Severens JL, Heymans J, Roekearts P, Voss G, Maessen JG. The need for more efficient use of existing Intensive Care Capacity: is Short Stay IC for CABG-patients the solution ? Chest, Seattle, United States. October 23-28, 2004.

- Severens JL Milne RJ. Different methods of discounting health outcomes in economic evaluation. A literature overview of theoretical arguments and empirical evidence. Health Technology Assessment International (HTAI). 1<sup>st</sup> annual meeting. Krakow, Poland. May 30 – June 2, 2004.
- Van\_Mastricht GAPG, Severens JL, Heymans J, Voss G, Maessen JG. Short stay intensive care for low-risk CABG-patients: a save and cost-effective approach. Health Technology Assessment International (HTAI). 1<sup>st</sup> annual meeting. Krakow, Poland. May 30 – June 2, 2004 (poster).
- Van\_Mastricht GAPG, Van\_Dielen F, Severens JL, Voss G, Greve JW. Short term cost-effectiveness of surgical treatment of morbid obesity, vertical banded gastroplasty (VBG) versus Lapband. Health Technology Assessment International (HTAI). 1<sup>st</sup> annual meeting. Krakow, Poland. May 30 – June 2, 2004 (poster).
- Brunenberg D, Joore M, Berghmans B, Severens JL. Development and face validity of a probabilistic markov model to evaluate the cost-effectiveness of stress urinary incontinence treatment in women. Health Technology Assessment International (HTAI). 1<sup>st</sup> annual meeting. Krakow, Poland. May 30 – June 2, 2004 (poster).
- Van\_Mastricht GAPG, Severens JL, Roekearts P, Heymans J, Franssen EJ, Maessen JG. Short Stay Intensive Care: the new standard treatment for postoperative care of low risk CABG-patients in the Netherlands? Voorjaars vergadering van de Nederlandse vereniging van Thoraxchirurgie. Nieuwegein, The Netherlands. May 14, 2004.
- Roekearts P., Heymans J, Van\_Mastricht GAPG, Severens JL, Franssen EJ, Voss G, Maessen JG. Short-Stay Intensive Care na coronair-chirurgie: een veilige en kosten-effectieve methode? Anesthesiologendagen 2004. Arnhem, The Netherlands. May 13-14, 2004.
- Van\_Mastricht GAPG, Severens JL, Franssen EJ, Roekearts P, Voss G, Maessen JG. Short Stay Intensive Care for low risk CABG-patients: a save and cost-effective approach? Nederlandse Intensivisten dagen 2004. Arnhem, The Netherlands. March 10-12, 2004.
- Severens JL. How much evidence is enough? Application of value of information theory to reimbursement decisions. Ispor 6<sup>th</sup> Annual European Congress. Barcelona, Spain. November 9-11, 2003 (panel session by Neumann P.).
- Steuten LMG, Vrijhoef HJM, Severens JL, Merode GG van, Spreeuwenberg C. Assessing the methodological quality of disease management programmes. International Society of Technology Assessment in Health Care (ISTAHC). Canmore, Canada. June 22-25, 2003 (poster).
- Abraham D, Bronkhorst EM, Severens JL, Felling A, Truin GJ. Dental insurance awareness in the Netherlands, patient knowledge of reimbursement versus factual coverage. 4th world conference International Health Economics Association (iHEA) San Francisco, United States. June 15-18, 2003 (poster).
- Kroese MEAL, Schulpen GJ, Bessems MCM, Landewé RB, Nijhuis FJ, Severens JL. Een pilotstudie naar het effect van een multidisciplinaire deeltijd dagbehandeling bij patiënten met fibromyalgie. NHG wetenschapsdag. Maastricht. 15 juni, 2003
- Abraham D, Bronkhorst EM, Truin GJ, Felling A, Severens JL. A dental utilization model validated for the Dutch dental sector. 18th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Berlin, Germany. June 9-12, 2002. (poster).
- Van Asselt ADI, Dirksen CD, Severens JL, Arntz A. Top-down or Bottom-up? The impact of patient selection on cost of illness results. 8<sup>th</sup> biennial conference, European Society for Medical Decision Making, Taormina, Italy June 2-5, 2002.
- Boll APM, Vliet JA van der, Severens JL. Screening for abdominal aortic aneurism: a Markov model. European Society for Vascular Surgery, 15th annual meeting. Lucerne, Switzerland, September 27-30, 2001.
- Severens JL. Medical Technology Assessment en budgettering. Symposium Naar een doelmatig en toegankelijk hulpmiddelenbeleid: hoortoestellen als voorbeeld. Maastricht, September 19, 2002.
- Hutten-Vollenbroek MMR, Wever D, Gorter M, Rinket J, IJzerman MJ, Severens JL, Hermens HJ. The cost-effectiveness of the Roessingh Rehabilitation program compared to usual care in patients with chronic low back pain. 1<sup>st</sup> World Congress of the ISPRM, Amsterdam, The Netherlands, July 7-13, 2001
- Welsing PMJ, Severens JL, Hartman M, Gestel AM van, Riel PLMC van, Laan RFJM. The development and validation of a Markov model for the evaluation of (new) treatments in Rheumatoid arthritis. Annual European Congress on Rheumatology (EULAR) 2001. Prague, Tjechoslowakia, June 13-16, 2001 (poster).

- Severens JL, Prins J, Bleyenberg G. Uncertainty in the economic evaluation of cognitive behaviour therapy in chronique fatigue patients. 17th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Philadelphia, United States. June 3-6, 2001.
- Severens JL, Verweij PE, Donnelly JP, Meis JFGM. Cost-effectiveness of liposomal amphotericin B for the empiric treatment of fever of unknown origin in bone marrow transplant patients: a decision analysis. Second European Conference on the Economics of Cancer. EORTC, Brussels, Belgium. September 3-5, 2000.
- Severens JL, Sonke GS, Laheij RJF, Verbeek ALM, Vries Robbé PF de. Efficient diagnostic testing: the probability modifying plot. 16th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). The Hague, The Netherlands. June 18-21, 2000.
- Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Validity of retrospective measurement of productivity costs. 16th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). The Hague, The Netherlands. June 18-21, 2000 (interactive poster presentation).
- Severens JL, Boll B, Vliet JA van der. Screening for abdominal aortic aneurysm: a Markov model. 16th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). The Hague, The Netherlands. June 18-21, 2000.
- Severens JL, Sonke GS, Verbeek ALM, Vries Robbé PF de. Efficient use of clinical tests for diagnosis of bladder outlet obstruction. Scientific meeting of the Netherlands Forum for Medical Decision Making (LFMB). Leiden, The Netherlands, June 16, 2000.
- Severens JL. Uncertainty in economic evaluation. International Health Economics Meeting of Organon, Akzo-Nobel. St.Michielsgestel, The Netherlands. April 12-14, 2000.
- Severens JL. Medical care and chronic fatigue syndrome. Course Cognitive behaviour therapy for chronic fatigue syndrome. Post Academic Education in Medicine (PAOG), Nijmegen, The Netherlands, April 7, 2000.
- Severens JL. Cost-effectiveness. Course Cognitive behaviour therapy for chronic fatigue syndrome. Post Academic Education in Medicine (PAOG), Nijmegen, The Netherlands, April 7, 2000.
- Kuijpers-Jagtman AM, Severens JL, Schols J. Cost-effectiveness analysis explained with a RCT in cleft lip and palate. Angle Society of Europe, 29th Annual Meeting, Going, Austria. February 2, 2000.
- Severens JL, Boll B. Modelling in economische evaluaties: een Markov model gericht op screening op Aneurysma Aorta Abodiminalis. Wetenschapsbijeenkomst Hoofdprogramma Hartfunctie en Circulatie (II.03). Nijmegen, The Netherlands. December 10, 1999.
- Duijnste JRD, Severens JL, Vollenbroek-Hutten M, IJzerman M. Kosten-effectiviteit van het Roessingh Rugscholingsprogramma. Meeting of the Dutch Society for Technology Assessment in Health Care. Amsterdam, The Netherlands. October 21, 1999.
- Jager GJ, Severens JL, Rosette JJMCH de la, Ruijs SHJ, Barentsz JO. How to determine the cost-effectiveness of MR imaging in pelvic disease. 16th annual meeting of the European Society for Magnetic Resonance in Medicine and Biology (ESMRMB). Sevilla, Spain. September 16-19, 1999
- Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Validity of measuring compensating mechanisms for absence from work as a basis for calculating productivity costs. 15th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Edinburgh, United Kingdom. June 20-23, 1999.
- Severens JL, Boo ThM de, Roosmalen MS van, Verweij P, Van der Wilt GJ. Validity of willingness to pay for non-decisional diagnostic information. 15th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Edinburgh, United Kingdom. June 20-23, 1999.
- Severens JL, Mulder J, Laheij RJF, Verbeek ALM. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs. 2nd world conference International Health Economics Association (iHEA). Rotterdam, The Netherlands. June 6-9, 1999 (poster).
- Severens JL, Mulder J, Laheij RJF. Reported compensating mechanisms for lost productivity related to duration of absence. 2nd world conference International Health Economics Association (iHEA). Rotterdam, The Netherlands. June 6-9, 1999 (poster).

- Severens JL. Cost-effectiveness research in orthodontic care. The International EURO-QUAL Conference. Noordwijkerhout. March 12 & 13, 1999.
- Severens JL. Principes en methoden van economische evaluaties. Academisch Centrum Tandheelkunde Amsterdam (ACTA). Amsterdam. 2 februari 1999.
- Kuijpers-Jagtman AM, PrahL-Andersen B, PrahL C, Konst EM, Severens JL, Peters HFM, Rietveld ACM, et al. Dutch three centra radonmised prospective clinical trial of presurgical infant orthopaedics. Sixth European Craniofacial Congress. Manchester, United Kingdom. June 15-18, 1999.
- PrahL C, Konst EM, Severens JL, PrahL-Andersen B, Kuijpers-Jagtman AM. Economic evaluation of infant orthopaedics in complete unilateral cleft lip and palate patients. Sixth European Craniofacial Congress. Manchester, United Kingdom. June 15-18, 1999.
- Severens JL. Kosten-effectiviteitsanalyse van PSOT. 14e Wetenschappelijke Vergadering Nederlandse Vereniging voor Schisis en Carniofaciale Afwijkingen. Rotterdam. 21 november 1998.
- Severens JL, Boo ThM de, Konst EM. Uncertainty of incremental cost-effectiveness ratios: fieller and bootstrap confidence intervals. 14th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Ottawa, Canada. June 7-10, 1998 (interactive poster presentation).
- Severens JL, Laheij RJF, Jansen JBMJ, Lisdonk EH van de, Verbeek ALM. Real productivity cost of short term absence from work: the case of persistent dyspepsia. 14th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Ottawa, Canada. June 7-10, 1998.
- Verweij PE, Bos JJ, Severens JL, Donnelly JP, Pauw BE de, Meis JFGM. Cost-effectiveness of Liposomal Amphotericin B for the Treatment of Invasive Fungal Infections in Neutropenic Patients. ICAAC
- Laheij RJF, Severens JL, Lisdonk EH van de, Verbeek, ALM. Randomised controlled trial of Omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. 14th annual meeting International Society of Technology Assessment in Health Care (ISTAHC). Ottawa, Canada. June 7-10, 1998.
- Severens JL, Braspenning JCC, Brokx JPL, Broek P van den. Economic evaluation of cochlear implants in The Netherlands. 4th European Symposium on Paediatric Cochlear Implantation. 's-Hertogenbosch, The Netherlands. June 14-17, 1998.
- Severens JL. De meting van kosten-effektiviteit. Symposium Meting van therapie-effekt bij stem-, spraak- en taalstoornissen. Nijmegen. 3 oktober 1997.
- Severens JL, PrahL C. Cost effectiveness of presurgical infant orthopaedics. 8th International Congress on Cleft Palate and related Craniofacial Anomalies, Singapore. September 7-12, 1997.
- Verweij PE, Severens JL, Donnelly JP, Vries Robbé PF de, Pauw BE de, Meis JFGM. An alternative strategy for managing invasive aspergillosis: a decision analysis. 13th congress of the International Society for Human and Animal Mycology, Parma, Italy. June 8-13, 1997.
- Severens JL, Verweij PE. Patiënten met een verhoogd risico voor invasieve aspergillosis. Symposium Geneesmiddelen onderzoek en implementatie van resultaten, Nederlandse Vereniging van Technology Assessment in de Gezondheidszorg (NVTAG), Rotterdam. 6 juni 1997.
- Weegels AJPG, Hof MA van 't, Severens JL. Validity and reliability of the diary method to record medical consumption on a periodical basis. 13th International meeting of the International Society of Technology Assessment in Health Care (ISTAHC), Barcelona, Spain. May 25-28, 1997 (poster).
- Severens JL, Laheij RJF, Jansen JBMJ, Lisdonk EH van de, Verbeek ALM. Overestimation of indirect costs in economic evaluation. 13th International meeting of the International Society of Technology Assessment in Health Care (ISTAHC), Barcelona, Spain. May 25-28, 1997 (poster).
- Severens JL, Braspenning JCC, Broek P van den. Cochlear implants in children: quality of life and cost-effectiveness. 13th International meeting of the International Society of Technology Assessment in Health Care (ISTAHC), Barcelona, Spain. May 25-28, 1997 (poster).
- Severens JL, Vries Robbé PF de, Verbeek ALM. Optimal sequence of diagnostic tests: illustrated by urinary tract infection. European Society for Medical Decision Making (ESMDM), Torino, Italy. June 16-18, 1996.

Severens JL, Prah C. Cost effectiveness of presurgical orthopaedic treatment (PSOT); preliminary results. 3rd European Congress on Health Economics, Stockholm, Sweden. August 20-22, 1995 (poster).

Prah C, Severens JL. Cost effectiveness of presurgical orthopaedic treatment (PSOT). 5th Craniofacial Congress, Copenhagen, Denmark. June 15-17, 1995.

#### Invited lectures

World of Health Care: 'International Business Models in Healthcare: Tough decision need strong and relevant evidence' September 26, 2019, Rotterdam.

Tjinghua-University, Department of Public Health: 'The power of health technology assessment: improving efficiency in health care in the Netherlands' June 19, 2019, Beijing, China.

Sino-Dutch Seminar on Health Care & Innovation: 'Initiatives of good management which improves efficiency/reduces cost in health care in the Netherlands' April 10, 2018, Beijing, China.

HTA-Seminars – University Gadj Mada: 'Principles of health technology assesment and economic evaluation: Should we use it? Can we use it? How to use it?' and 'Introduction to Economic Modelling' Nov 26<sup>th</sup> 2018, Yogyakarta, Indonesia.

EuLAR Annual European congress: 'Can biosimilars significantly change health economics?' June 11, 2014, Paris, France.

CIS pharmaceutical forum: 'International transferability of cost-effectiveness evidence' February 11, 2014, Moscow, Russia

TU-Delft, Seminar series: 'Kosten en baten van medische technologie' December 13, 2013, Delft The Netherlands.

ILDS meeting Grand Challenges in Global Skin Health (International League of Dermatological Societies: 'Health Economic Evaluation; Simultaneously modelling health impact, budget impact and cost-effectiveness' November 28-29, 2013, London, UK.

IPC Think Tank (International Psoriasis Council): 'Health Economics; a view from Europe' November 22-23, 2013, Boston, USA.

ESCEO-conference: 'Cost-effectiveness of pharmacological interventions in osteoarthritis: a review' April 19, 2013. Rome, Italy.

EPPOSI workshop on Societal Benefits Approach in HTA: 'Some Facts and Some Future regarding Economic Evaluations' February 4, 2013 Brussels, Belgium.

European Dermatology Forum: 'Impact of health economic decisions on academic medicine and patient care; the health economist's perspective' 16<sup>th</sup> EDF-meeting, January 26, 2013, Luzern, Switzerland.

ESCEO-meeting Health Economics in Osteoarthritis: 'Cost-effectiveness of pharmacological interventions in osteoarthritis: a review' December 4, 2012. Geneva, Switzerland

Ministerie van Volksgezondheid, Welzijn en Sport: "Geloof in sprookjes en/of bewijs? De rol van economische evaluaties bij besluitvorming over vergoeding en gebruik van medische technologie" Seminar series, October 1, 2012, The Hague, The Netherlands.

Erasmus Medical Centre, Dept of Public Health: "Economic modeling and decision making: why make it easy?" Seminar series, September 10 2012, Rotterdam, The Netherlands.

Oxford Outcomes / Medtronic: "Practical issues in implementing local and national HTA: the challenge of generalisability...". HTAi Satellite Symposium Local and National HTA: Finding the Balance of Responsibilities, June 24 2012, Bilbao, Spain.

Centre de Recherche Public CRP Santé: "HTA methods for evaluating companion diagnostics: should the doctor know?" 1<sup>st</sup> annual health economics and personalized medicine symposium, June 18-19 2012, Luxembourg, Luxembourg.

EULAR: “Key concepts for understanding the health economics of rheumatoid arthritis”. EULAR conference, June 6-11 2012, Berlin, Germany.

ISPOR Russia HTA Chapter and the Research Center for Clinical & Pharmacoeconomic Evaluation and Pharmacoeconomics (RC CEE&Ph), Russian State Medical University: “Health technology Assessment: should we use it? Can we use it? How to use it?” International scientific and practical conference ‘International experience in HTA and prospects of its implementation in Russia’, May 21 2012, Moscow, Russia.

PFIZER Ukraine: “Use of cost-effectiveness evidence: The Dutch case”. Symposium ‘Availability of antibacterial therapy’, September 16 2011, Kyiv, Ukraine.

NVTAG: “What’s new? Een kleine geschiedenis van bijna alles”. NVTAG Lustrum Symposium ‘Back to the Future’, April 7 2011, Rotterdam, The Netherlands.

Alzheimer's Drug Discovery Foundation: “The value of primary data in cost-effectiveness modelling of diagnostic technologies; WP4: MedicalTechnology Assessment in the LeARN-project”. 6<sup>th</sup> International Pharmacoeconomic Conference on Alzheimer’s Disease (IPECAD), February 3-4 2011, London, United-Kingdom.

Lions-club Venray: “Economische evaluaties van innovaties in de gezondheidszorg: de 4e horde voor een sprookje?”. February 8 2011.

CBO Centraal BegeleidingsOrgaan // Kwaliteitsinstituut voor de gezondheidszorg: “Kosten-effectiviteit bij richtlijnontwikkeling en -implementatie: Meer gedoe of noodzakelijk?” EBRO Master-class, CBO, September 23 2010 Utrecht.

National University of Kyiv-Mohyla academy, School of Public Health: “Background and principles of HTA and economic evaluation of health care programmes”. September 21 2010, Kyiv, Ukraine.

Ukraine Ministry of Health: “Use of cost-effectiveness evidence: the Dutch case (and a bit of NICE)”. Symposium on HTA. Ministry of Health, September 20 2010, Kyiv, Ukraine.

University of Technology Sydney: “It is always too early... Pro’s and cons of coverage with evidence development”. CHERE-seminar series. March 17 2010, Sydney, Australia.

GlaxoSmithKline: “Transferability of cost-effectiveness data between countries”. GSK-Expert panel: Emerging Methods in HTA, March 5 2010, London, United-Kingdom.

Aberdeen University: “Transferability of cost-effectiveness studies; theory, practise, and health state valuation”. ESRC-seminar series. October 29 2009, Aberdeen, Scotland.

American College of Rheumatology: “Trials, monitoring, and/or modeling? (Im-)possibilities in economic evaluation in rheumatology”. Study group economic evaluations, ACR conference, October 19 2009, Philadelphia, USA.

AMGEN: “Coverage with evidence development; a challenge to us all”. Amgen Pharmacoeconomics meeting, 9 November 2008, Athens, Greece.

XCellerate: “Economic evaluation and decision making in uncertainty”. NHS Innovations London, Launch meeting XCellerate Health Outcomes, 16 October 2008, London, United Kingdom.

Van Hoytema Stichting: “Economische aspecten van medische technologie: Een ongewenst sprookje?” Lustrumcongres Van Hoytema stichting. 19 September 2008. Enschede, The Netherlands.

German Association of Research-Based Pharmaceutical Companies – VFA: “The Use of Cost-effectiveness Modelling and Value of Information Analysis”. German Association of Research-Based Pharmaceutical Companies - VFA, 14 February 2008, Berlin, Germany.

German Association of Research-Based Pharmaceutical Companies – VFA: “Guideline for outcomes research”. German Association of Research-Based Pharmaceutical Companies - VFA, 14 February 2008, Berlin, Germany.

European Association for Clinical Pharmacology and Therapeutics: “Pharmacoeconomics and reimbursement of new drugs”. 8<sup>th</sup> Congress of the European Association for Clinical Pharmacology and Therapeutics. 31 August 2007, Amsterdam, The Netherlands.

AZM, afdeling Oncologie: “Doelmatigheidsonderzoek in de oncologie”. Symposium Toegepast en fundamenteel onderzoek in de oncologie. 25 May 2007, Maastricht, The Netherlands.

College voor zorgverzekeringen: "Kosten-effectiviteitsmodellen: zin en/of onzin?" Commissie Farmaceutische Hulp, College voor zorgverzekeringen. 7 May 2007, Utrecht, The Netherlands.

European Society Medical Oncology: "Doelmatigheid van nieuwe dure geneesmiddelen: een ongewenst sprookje?" Annual Conference European Society Medical Oncology; Nederlandse Avond. Istanbul, Turkey. 1 Oktober 2006.

Nederlandse Vereniging voor Reumatologie: "Economische argumenten bij keuzen in de zorg; hoe kunnen we voorkomen dat een sprookje uitkomt?" Congres Nederlandse Vereniging voor Reumatologie. Veldhoven, 6 september 2006.

ROCHE: "What are we willing to pay? The value of a statistical life in different life-saving societal interventions". 11<sup>th</sup> Congress of the European Association of Hospital Pharmacists, Geneva, Switzerland. 22 March 2006.

NVTAG: "Economic evaluations of implementation strategies". Najaarssymposium Economische aspecten van richtlijnen en richtlijntoepassing NVTAG i.s.m. ZONMW en CBO. 10 November 2006, Utrecht, The Netherlands.

McMaster University, PATH: "Economic Evaluation of Implementation of Technology Assessment Results in Health Care". PATH seminar series, McMaster University, Hamilton Canada, June 13th 2005.

NEFARMA: "Financing of innovative biotech products in the Netherlands". Value creation in the health care chain Nefarma conference: Biotechnology drugs: a blessing for the patient, a boost for the economy 2 November 2004.